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Abstract 
Genetic disposition and response of blood lipids to diet. 
Studies on gene-diet interaction in humans. 
Ph.D. thesis by Rianne M. Weggemans, Division of Human Nutrition and Epidemiology, 
Wageningen University, The Netherlands. January 17, 2001. 
Even though a cholesterol-lowering diet is effective for most people, it is not for all. 
Identification of genetic determinants of the serum lipid response to diet may be of help in the 
identification of subjects who will not benefit from a cholesterol-lowering diet. It may also 
clarify the role of certain proteins in cholesterol metabolism. The objective of our research 
was to determine whether genetic polymorphisms affect the response of serum lipids to diet in 
humans. 
We first assessed sex differences in the response of serum lipids to changes in the diet. 
Men had larger responses of total and low-density lipoprotein cholesterol to saturated fat and 
cafestol than women. There were no sex differences in the responses to trans fat and dietary 
cholesterol. We also used these data to study the effect of 11 genetic polymorphisms on 
responses of serum lipids to the various dietary treatments. Apoprotein E, A4 347 and 360, 
and cholesteryl-ester transfer protein Taqlb polymorphisms affected the lipid response to diet 
slightly. 
We further studied the effect of the apoprotein A4 360-1/2 polymorphism on response 
of serum lipids to dietary cholesterol in a controlled trial specially designed for this purpose. 
The apoprotein A4 360-1/2 polymorphism did not affect the response of serum lipids to a 
change in the intake of cholesterol in a group of healthy Dutch subjects who consumed a 
background diet high in saturated fat. 
Although it is not directly related to genetic polymorphisms and lipid response, we 
finally reviewed the effect of dietary cholesterol on the ratio of total to high-density 
lipoprotein cholesterol, which is a more specific predictor of coronary heart disease than 
either lipid value alone. Dietary cholesterol raised the ratio of total to high-density lipoprotein 
cholesterol. 
In conclusion, the effect of genetic polymorphisms on serum lipid response to diet is 
small. It is therefore not possible to identify individuals who will not benefit from a 
cholesterol-lowering diet on the basis of a specific genetic polymorphism. 
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General introduction 
Chapter 1 
Background 
World wide, cardiovascular diseases are a substantial source of chronic disability and 
health costs (1). In the Netherlands, coronary heart disease is the most prevalent 
cardiovascular disease. During the past 20 years, death as a result of cardiovascular disease 
has decreased. This decrease is caused by a reduced incidence of cardiovascular disease and 
by improved care of patients with cardiovascular disease. However, one of the side effects is 
that the number of patients with cardiovascular disease has increased. In addition, the 
improved prognosis of coronary heart disease has increased the probability of another 
cardiovascular event (2). Prevention of cardiovascular disease should be targeted to the 
general population to postpone time of onset of disease. In addition, people with 
cardiovascular disease should be targeted for secondary prevention to improve quality of life. 
The pathological condition that underlies coronary heart disease is atherosclerosis, 
which involves lesions in the arterial vessel wall. These lesions contain large amounts of 
lipids, a large proportion of which is cholesterol that comes from the blood. In blood, most of 
the cholesterol is transported in low-density lipoprotein (LDL) and a small proportion is 
transported in high-density lipoprotein (HDL). High concentrations of serum LDL-cholesterol 
are a risk factor of coronary heart disease. However, on the contrary, high concentrations of 
HDL-cholesterol protect against coronary heart disease (3). 
Subjects who suffer from overt cardiovascular disease or who are at high risk of 
cardiovascular disease should be targeted for lifestyle intervention and, where appropriate, 
drug therapies. One of the recommended changes in lifestyle is a lipid-lowering diet. In this 
diet, total energy intake should comprise less than 30 % fat, total fat intake should comprise 
less than one third as saturated fat, and intake of dietary cholesterol should be less than 300 
mg per day. The prevention goals for blood lipids are concentrations of total cholesterol less 
than 5.0 mmol/L and of LDL-cholesterol less than 3.0 mmol/L (4). 
However, even though a lipid-lowering diet is effective for most people, it is not for 
all. The effect of a lipid-lowering diet is to some extent reproducible in a subject, which 
indicates that it may be in part an innate characteristic of a subject (5,6). Identification of 
genetic factors that are related to the lipid response to diet may be of help in the identification 
of subjects who will not benefit from a cholesterol-lowering diet. It may also clarify the role 
of certain proteins in cholesterol metabolism. 
This introduction gives a concise overview of cholesterol metabolism and the effect of 
diet on serum lipids. It then discusses the role of genetic polymorphisms in determining the 
response of serum lipids to diet and presents a number of candidate genes that are studied in 
this thesis. The general objective and outline of the thesis are given at the end of this chapter. 
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Cholesterol metabolism 
The steroid cholesterol is an essential component of the cell membrane and is a 
precursor in the synthesis of bile acids and steroid hormones (7). In addition to cholesterol 
obtained from diet, there is also de nova Synthesis of cholesterol from acetate in the liver and 
in peripheral tissues. 
As reviewed in (8), cholesterol metabolism consists of two pathways, the exogenous 
pathway and the endogenous pathway (Figure 1.1). The exogenous pathway concerns the 
transport of dietary cholesterol and triglycerides from the intestine to the liver. Dietary 
cholesterol and triglycerides are processed in the intestine and packaged into chylomicrons. 
Intestinal fatty acid binding protein (FABP2) is essential for the uptake, metabolism and/or 
transport of long-chain fatty acids. Microsomal triglyceride transfer protein (MTP) is essential 
for the assembly and secretion of chylomicrons from intestinal cells into lymph. These 
chylomicrons subsequently enter the circulation. The capillary vessel wall of peripheral 
tissues contains lipoprotein lipase (LPL). Apolipoprotein (apo) C-II, which is part of the 
chylomicron, activates LPL. Activated LPL hydrolyzes the triglycerides in the core of 
chylomicrons into free fatty acids, which subsequently enter fat and muscle cells. In this way, 
chylomicrons are converted into chylomicron remnants, which then pick up cholesteryl-esters 
from HDL (this is part of endogenous pathway). These cholesterol-enriched chylomicron 
remnants are efficiently cleared by LDL-receptor and LDL-receptor related protein (LRP) (9), 
which involves apoB48 and apoE on the surface of remnants. Cholesterol is used in a number 
of ways in the liver. It may be esterified and stored in liver cells or used for synthesis of cell 
membranes. It may also be converted into bile acids and subsequently excreted from the body. 
The endogenous pathway consists of two interrelated processes. One co-ordinates 
movement of cholesterol and triglycerides from the liver to peripheral tissues and the other 
concerns their transport from peripheral tissues back to the liver. This is called the reverse 
cholesterol transport. As part of the former process, liver cells secrete cholesterol and 
triglycerides into blood in the form of very low-density lipoproteins (VLDL). MTP is 
essential for the assembly and secretion of VLDL. Triglycerides in VLDL are hydrolyzed by 
LPL, similarly to those in chylomicrons. This results in the formation of smaller intermediate 
density lipoproteins (IDL), which can be cleared from plasma by the liver through LDL-
receptors and LRP or is converted to LDL by LPL or hepatic lipase. LDL is then either 
directly removed by peripheral cells or liver cells through the interaction of apoB-100 with 
LDL-receptors. 
As part of the other process of the endogenous pathway, the reverse cholesterol 
transport, nascent high-density lipoprotein (HDL), which is synthesized in liver and intestinal 
cells, changes into HDL3 by taking up free cholesterol from extrahepatic cells. This 
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1. Een cholesterolverlagend dieet is effectiever bij mannen dan bij vrouwen. Dit 
proefschrift. 
2. De conclusie van McCombs et al (NEngJMed 1994; 331:706-10) dat het 
apoprote'me A4 360-2 allel de cholesterolrespons op voedingscholesterol 
vermindert, is waarschijnlijk gebaseerd op een toevalsbevinding. Dit proefschrift. 
3. Voor de primaire preventie van hart- en vaatziekten is het niet van belang of je 
regelmatig een lange duurloop doet of korte sprints, zolang het energieverbruik 
maar gelijk is. Sesso et al. Circulation 2000; 102:981-6. 
4. De behandeling van essentiele hypertensie kan effectiever worden door medicatie 
af te stemmen op het 24-uurs ritme van de bloeddruk. Smolanski & Portaluppi. 
Am Heart J1999; 137.S14-24. 
5. Slechts 5 tot 10 % van alle vrouwen in de overgang heeft baat bij 
hormoonsuppletie. Barrett-Connor. De Anatomische Les, 2000. 
6. Voor de preventie van hart- en vaatziekten zijn de meeste mensen meer gebaat bij 
een verandering in leefstijl (lichaamsbeweging, niet roken, goede voeding) dan bij 
het gebruik van vitamine - en mineralensupplementen. 
7. Voor de behandeling van RSI (repetitive strain injuries, muisarm) is de 
verandering in fysieke werkhouding net zo belangrijk als de verandering in 
mentale werkhouding. 
8. Het succes van vernieuwingen is afhankelijk van de mate waarin ze aansluiten bij 
de bestaande situatie. 
Stellingen bij het proefschrift 
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General introduction 
cholesterol is esterified by lecithinxholesterol acyltransferase (LCAT), which uses apoA-I 
and apoA-IV as co-factors. The cholesteryl esters migrate to the core of the HDL3. Further 
uptake of cholesterol and action of LCAT results in larger-sized and cholesteryl-rich HDL2a-
As HDL2a becomes more enriched with cholesteryl esters, apoproteins C-II and C-III are 
picked up from other lipoproteins. Subsequently, cholesteryl esters are transferred to 
chylomicrons, VLDL, IDL, and LDL in exchange for triglycerides by the action of cholesteryl 
ester transfer protein (CETP). This process results in triglycerides-rich HDL2b and enables the 
hepatic uptake of cholesteryl esters from VLDL, IDL, and LDL. HDL2b can be removed from 
circulation by the HDL-receptor, also known as scavenger receptor Bl. HDL2b can also be 
converted into the form of HDL3 by hepatic lipase, which hydrolyzes the triglycerides in 
HDL2b(8,10). 
Effect of diet on lipid concentrations 
Diet affects lipid concentrations in the blood. At a population level, replacement of 
carbohydrates by saturated fat and the addition of dietary cholesterol increase concentrations 
of LDL- and HDL-cholesterol, whereas replacement of carbohydrates by m-unsaturated fat 
decreases LDL-cholesterol and increases HDL-cholesterol concentrations (11-14). Trans fat 
increases LDL-cholesterol concentrations in the same way as saturated fat, whereas it 
decreases HDL-cholesterol concentrations as compared to saturated fat (15). In a similar way, 
addition of cafestol to diet increases LDL-cholesterol and slightly decreases HDL-cholesterol 
concentrations (16). 
The precise mechanisms determining the response of serum lipids to diet are not 
known. The response of LDL-cholesterol to saturated fat and dietary cholesterol may be 
mediated in part by the number of hepatic LDL-receptors that affect the clearance of LDL-
cholesterol from the blood. Down-regulation of the cholesterol synthesis in liver, increased 
CETP-activity, and enhanced synthesis of bile acids may also play a role in the mechanism 
that determines this lipid response (17,18). The most plausible mechanism by which cafestol 
affects LDL-cholesterol concentrations is through the sterol regulatory element binding 
protein (SREBP) pathway (19). 
The response of serum lipids to diet varies considerably among subjects. A large part 
of this heterogeneity in responses is not reproducible and is due to random fluctuations within 
subjects. Another part of the heterogeneity in response is reproducible and may partly be an 
innate characteristic of a subject (5,6). 
The mechanism underlying the differences in response between subjects is still 
obscure. It is probably heterogeneous, because various stages in cholesterol metabolism, such 
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General introduction 
as absorption of cholesterol, inhibition of cholesterol synthesis, excretion of steroids, 
receptor-mediated clearance of LDL, LDL production, and accumulation of cholesterol in the 
body, may all contribute to response (20). 
Possible role of genetic variation 
Genes are parts of DNA that encode an enzyme or structural protein. Within a gene, 
coding sequences are interrupted by intervening sequences that are no part of the final gene 
product. Small flanking regions of DNA at both ends of the gene are important in the 
initiation and control of transcription, and mutations in these regions can affect the 
functioning of the gene. Many different forms of a gene may exist as a result of individual 
mutations. These are called alleles. Genes are called polymorphic when at least two alleles 
occur at a frequency of more than 1 % in a population (21). 
Variation in DNA or genetic polymorphisms may affect the response of serum lipids 
to diet by influencing the production, composition and/or function of proteins in the 
cholesterol metabolism. There are many proteins (and thus genes) that play a role in various 
pathways of cholesterol metabolism. This thesis describes the effect of 11 polymorphisms of 
9 genes on the lipid response to diet (Figure 1.1, Table 1.1). 
As reviewed in detail by others (22-24), evidence that polymorphisms affect lipid 
responses is growing in the case of the APOE polymorphism, which has been most 
extensively studied, and for polymorphisms in the APOA1, APOA4, APOB, CETP, and LPL 
genes. However, results of studies of the effects of genetic polymorphisms on response are 
often inconsistent. There are several explanations for these inconsistencies. One possible 
explanation is that most of the studies lacked statistical power to detect existing effects of 
polymorphisms on lipid response due to small numbers of subjects. Another explanation is 
that polymorphisms only affect lipid responses to specific dietary changes, such as a change 
in dietary cholesterol, a change in dietary fat, or a combination of a change in dietary 
cholesterol and fat. Yet another explanation is that polymorphisms have sex-specific effects, 
they may affect the response only in men or only in women. 
Objective and outline of the thesis 
The objective of this research was to determine whether genetic polymorphisms affect 
the response of serum lipids to diet in humans. 
In Chapter 2 we assess sex differences in the response of serum lipids to changes in 
the diet. For this purpose, we pooled data on the serum lipid response to diet from 26 former 
15 
Chapter 1 
dietary trials involving 248 men and 243 women. These data were also used to study the 
effect of genetic polymorphisms on response of serum lipids to diet. Chapter 3 considers the 
effect of the APOE2/3/4 polymorphism on serum lipid response and reviews the effect of this 
polymorphism as determined in other studies. Chapter 4 describes the effects of 10 other 
candidate polymorphisms on serum lipid response. In Chapter 5, we describe the results of a 
controlled dietary trial of the effect of APOA4 360-1/2 polymorphism on response of serum 
lipids to dietary cholesterol. Although it is not directly related to genetic polymorphisms and 
lipid responses, the data of this trial were also used in a meta-analysis of the effect of dietary 
cholesterol on the ratio of total cholesterol to HDL-cholesterol (Chapter 6). Finally, the main 
outcomes of the studies of the effects of genetic polymorphisms on serum lipid response are 
discussed in Chapter 7. This chapter also focuses on methodological issues of studies on 
gene-diet interaction and issues in comparing such studies. In addition, it discusses the 
feasibility of genetic tests to detect diet-sensitivity and possible directions for future research 
with regard to gene-diet interactions in lipid metabolism. 
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Differences between men and women in the 
response of serum cholesterol to dietary changes 
Rianne M. Weggemans, Peter L. Zock, Rob Urgert, Martijn B. Katan 
Abstract- Mild hypercholesterolemia is initially treated by diet. However, most studies of diet 
and cholesterol response were done in men, and it is unknown whether women react to diet to 
the same extent as men. We therefore studied sex differences in the response of serum 
cholesterol and lipoproteins to diet. 
We measured responses of serum cholesterol to a decrease in dietary saturated fat in 
seven trials involving 126 men and 147 women, to a decrease in dietary trans fat in two trials 
(48 men and 57 women), and to a decrease in dietary cholesterol in eight trials (74 men and 70 
women). We also measured responses to the coffee diterpene cafestol, which occurs in 
unfiltered coffee, in nine trials (72 men and 61 women). All subjects were lean and healthy. 
The response of total cholesterol (± standard deviation) to a decrease in the intake of 
saturated fat was larger in men (-0.62 ± 0.39 mmol/L) than in women (-0.48 ± 0.39 mmol/L; 
95% confidence interval (CI), 0.04 to 0.23 mmol/L). The response of total cholesterol to a 
decrease in the intake of cafestol was also larger in men (-1.01 ± 0.49 mmol/L ) than in 
women (-0.80 ± 0.49 mmol/L; 95% CI, 0.04 to 0.39 mmol/L). Responses to trans fat and to 
dietary cholesterol did not differ between men and women. 
In conclusion, men have larger responses of total cholesterol and LDL-cholesterol to 
saturated fat and cafestol than women. 
Eur J Clin Invest 1999; 29:827-834 
Chapter 2 
Introduction 
Mild hypercholesterolemia, which is defined as a total cholesterol level over 5.2 
mmol/L, is initially treated by a diet low in saturated fat and cholesterol, regardless of the sex 
of the patient (1-4). However, this dietary approach is based on evidence from trials most of 
which only comprised men (5-8). It is therefore not known whether dietary treatments to 
lower cholesterol should differ between men and women. 
Some studies showed that the sex of a subject affects responses of total, low-density 
lipoprotein (LDL-), and high-density lipoprotein (HDL-) cholesterol to diets low in fat and 
cholesterol or with a high content of polyunsaturated fat (9-13), but others failed to confirm 
this (14-16). 
We therefore compared diet-induced responses of serum total cholesterol and LDL-
and HDL-cholesterol in 248 women and 243 men who participated in 26 controlled trials 
performed at our department between 1976 and 1996. 
Materials and methods 
Subjects, diets and experimental design 
We pooled data of 26 controlled trials on diet and response, which had all been 
performed at our department between 1976 and 1996. In seven trials saturated fatty acids 
were exchanged for cw-unsaturated fatty acids or carbohydrates (referred to below as 
saturated fat trials) (17-23), in two trials trans fatty acids were exchanged for cw-unsaturated 
fatty acids {trans fat trials) (21-22), in eight trials the amount of dietary cholesterol was 
modified {dietary cholesterol trials) (24-28), and in nine trials the coffee diterpenes cafestol 
and kahweol were given {cafestol trials) (29-34) (Figure 2.1, Table 2.1). These diterpenes are 
responsible for the cholesterol-raising effect of unfiltered coffee. The amounts which were 
consumed by the subjects of these trials were within the normal range of consumption (35). 
Results of individual trials have been published elsewhere (17-34). Seven trials had a cross-
over design (18, 21-23, 33), 14 a parallel design with a control group (17, 19, 20, 24, 26, 27, 
28, 31, 32, 34), and five a before-and-after or linear design without a control group (25, 29-
32). 
Subjects received all their foods in 12 trials with saturated fat, trans fat, or dietary 
cholesterol (17-24, 26-28). In four trials of dietary cholesterol subjects received eggs as a 
supplement during the treatment period and guidelines for a diet low in cholesterol during the 
control period (24-27). In one other trial of dietary cholesterol, subjects received all foods 
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All 26 Trials 
924 responses 
243 men / 248 women 
249 participated in more than one trial 
7 Saturated Fat Trials 
376 responses 
126 men /147 women 
78 participated in more than one saturated fat trial 
2 Trans Fat Trials 
115 responses 
48 men / 57 women 
10 participated in more than one trans fat trial 
8 Dietary Cholesterol Trials 
282 responses 
74 men / 70 women 
77 participated in more than one cholesterol trial 
9 Cafestol Trials 
151 responses 
72 men / 61 women 
18 participated in more than one cafestol trial 
Figure 2.1 Overview of the trials indicating the number of responses measured, the number of 
participating men and women, and the nature of the dietary intervention. Saturated fat trial, 
exchange of saturated fatty acids for c«-unsaturated fatty acids or carbohydrates; trans fat trial, 
exchange of monounsaturated trans-fatty acids for cw-unsaturated fatty acids; dietary cholesterol 
trial, addition of dietary cholesterol to the diet; and cafestol trial, supplementation with the coffee 
diterpenes cafestol and kahweol. 
during the treatment period and received dietary guidelines during the control period (28). In 
the nine cafestol trials subjects received coffee, coffee grounds, coffee oil, or cafestol and 
kahweol as a supplement and consumed their habitual diet throughout the trial (29-34). 
Participants were asked to maintain their usual patterns of activity, their smoking habits, and 
their use of oral contraceptives during the trials. They recorded in diaries any signs of illness, 
medications used, or other factors that might have affected the outcome of the study. The 
number of participants per trial ranged from 3 to 94 (median of the number of participants was 
23), and the duration of the treatment ranged from 1.5 to 14 weeks (median duration was 3 
weeks). 
In the cross-over trials, subjects were randomized to the sequence of the various 
treatments (18,21-23, 33) and in the parallel trials, subjects were randomized to one 
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Chapter 2 
of the various treatments (17, 19, 20, 24, 26-28, 31, 32, 34). In five of the nine cafestol trials 
participants and investigators were blinded to the nature of the treatment (30-33). Lab 
personnel were never aware of the subject's treatment. Cholesterol levels were determined in 
at least two serum samples per treatment which were obtained on separate days. All sera from 
one subject were analyzed within the same run. The coefficient of variation within one run for 
control samples ranged from 0.7 to 2.9 %. In all trials the accuracy was checked by the 
analysis of three serum pools of known value provided by the Centers for Disease Control 
(Atlanta, GA). The mean bias with regard to the target values of the Centers for Disease 
Control pools ranged from -2 % to 1.1 % for total cholesterol, from -3.2 % to 3.3 % for HDL-
cholesterol, and from -1.5 % to 10 % for triglycerides (17-34). 
The subjects were healthy as indicated by a medical questionnaire, and by the absence 
of anemia, glucosuria, and proteinuria. The protocols, which were approved by the appropriate 
Ethical Committee, were explained to the subjects and informed consent was obtained from 
all subjects. 
In order to protect the privacy of subjects and assure blinding we assigned new 
identification numbers to all subjects. To check for errors introduced during the coding and 
during the amalgamation of the data from the 26 trials, we determined the presence of DNA 
sequences unique to the X and Y chromosome (36). Out of 512 subjects for whom data were 
available one woman had been erroneously coded as a man; the sex of the other 511 subjects 
agreed with that in the pooled data files. 
For the present analyses we pooled serum cholesterol responses to saturated fat of 126 
men and 147 women, responses to trans fatty acids of 48 men and 57 women, responses to 
dietary cholesterol of 74 men and 70 women, and responses to cafestol of 72 men and 61 
women (Table 2.2). We excluded data from subjects who received a control diet or a placebo 
treatment throughout a trial. We did not analyze responses of LDL-cholesterol to dietary 
cholesterol, because these were available for only 47 of the 144 subjects. Age was recorded 
and body mass index, weight change, and serum cholesterol levels were measured as 
described (17-34). Baseline cholesterol levels were measured before the start of the study, 
when subjects consumed their habitual diets. 
Statistical analysis 
The way we calculated individual responses of cholesterol depended on the design of 
each trial, which was either a cross-over, a parallel, or a before-and-after design. In the trials 
with a cross-over or parallel design we defined individual responses of cholesterol as the level 
of serum cholesterol at the end of the treatment that lowered cholesterol minus the level at the 
end of treatment that increased cholesterol. In the trials with a before-and-after 
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Table 2.2 Baseline characteristics (mean ± standard deviation) of 
men and women in the various trials. 
Saturated fat trials 
N 
Total cholesterol level (mmol/L) 
Body mass index (kg/m2) 
Age (years) 
Trans fat trials 
N 
Total cholesterol level (mmol/L) 
Body mass index (kg/m2) 
Age (years) 
Dietary cholesterol trials 
N 
Total cholesterol level (mmol/L) 
Body mass index (kg/m2) 
Age (years) 
Cafestol trials 
N 
Total cholesterol level (mmol/L) 
Body mass index (kg/m2) 
Age (years) 
Men 
126 
4.88 ± 0.93 
22.5 + 2.7 
28 ± 12 
48 
4.88 ± 0.77 
21.8+ 1.9 
24 + 8 
74 
5.05 ± 0.81 
23.5 + 3.2 
37 + 16 
72 
4.54 ± 0.66 
22.1 ±2.0 
26 ±8 
Women 
147 
5.12 ± 0.89 
22.4 + 2.8 
28+ 12 
57 
4.91 + 0.72 
21.7 + 2.4 
25 + 8 
70 
5.42 + 1.43 
23.2 ± 3.3 
39+ 17 
61 
4.58 + 0.60 
22.0 ± 2.5 
24 + 5 
To convert values for total cholesterol level from mmol per liter to mg per deciliter, 
divide mmol per liter by 0.02586. 
design in which the treatment lowered cholesterol, we defined individual responses as the 
level of cholesterol at the end of the treatment minus the level of cholesterol before the 
treatment. In the trials with a before-and-after design in which the treatment increased 
cholesterol, we defined individual responses as the level of cholesterol before the treatment 
minus the level at the end of the treatment. In one dietary cholesterol trial (25) and seven 
cafestol trials (29, 31,32, 33, 34), we used the level of baseline cholesterol to calculate the 
response. 
25 
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We used different methods to estimate the differences between men and women in 
their responses of cholesterol. To adjust for potentially confounding factors, we used the 
average individual response as independent variable in a two-factor and multiple regression 
model. We calculated the average response of each subject over trials with a similar dietary 
treatment, as well as their average body mass index and age, because 28 per cent of the 
subjects participated in two or more trials with a similar dietary treatment; 51 per cent of all 
subjects participated in more than one trial. 
Two-factor regression model 
The two-factor regression model included as independent factors the sex of the subject 
and additional factors indicating in which trial the individual's cholesterol response had been 
measured. If a trial consisted of more than one treatment, we created factors indicating each 
treatment within a trial. Inclusion of these trial factors allowed us to correct for differences 
between trials in e.g. characteristics of the background diet, whether the diet was controlled or 
uncontrolled, or time of the year during which the trial had been performed. If subjects 
participated in more than one trial with a similar dietary treatment the factors of these trials 
were set to a value reciprocal to the number of times a subject had participated. For instance, 
if a subject participated in two trials, the factor for each trial was set to Vi. In this way, we 
could adjust the individual's mean response for the effect of various trials. In the two-factor 
regression model, the mean cholesterol response of men and women was calculated by a least 
squares method after correction for the trial in which the response was measured. 
Multiple regression models 
In a multiple regression model, differences in responses between sexes were estimated 
after adjustment for trial and for the subjects' age, body mass index, and change in weight 
during the trial. We lacked information about the age of 21 subjects, body mass index of 65 
subjects, and change in weight during the trial of 48 subjects. For these subjects we set age to 
25 years, body mass index to 25 kg/m , and change in weight to 0.0 kg. For all subjects we 
created dummy variables that indicated whether the information about a characteristic was 
available or not. In this way data on the response of cholesterol of all subjects could be 
included in the multiple regression model. 
We did not adjust for baseline cholesterol level in our primary analyses because 
baseline cholesterol level was part of the response in one dietary cholesterol trial and seven 
cafestol trials. We excluded these eight trials to study the effect of baseline cholesterol on 
response of cholesterol. In a regression analysis we estimated the difference in response 
between men and women after adjustment for trial, age, body mass index, change in weight 
during the trial, and baseline cholesterol level. 
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We also analyzed the data using various other models. For a crude analysis, the mean 
responses of the men and women were calculated for each treatment within a trial. For each 
type of treatment - saturated fat, trans fat, cholesterol, and cafestol - these means were 
averaged weighting for the reciprocal of their standard error. In this way differences between 
trials in the precision of the observed mean responses were taken into account. A mixed-
model regression analysis was applied to the trials with dietary cholesterol and we analyzed all 
trials without taking into account that some subjects had participated more than once, thus 
treating all responses of the same subjects as independent observations. We also used 
predicted responses as independent factors in a regression model. These predicted responses 
were calculated by coefficients from published meta-analyses on changes in serum cholesterol 
and lipoproteins to changes in the amount of dietary fatty acids and cholesterol (5, 6, 35, 37, 
38). In yet other models, we expressed the cholesterol response as percentage change from the 
serum cholesterol level at the end of the control or baseline period and also as Z-scores 
relative to the average response of the group on the same treatment. All these models yielded 
similar differences in responses between men and women, which confirmed the robustness of 
the models presented here (39). 
To check that differences in the design of trials did not bias our results, we also 
performed the analyses without data from trials with a before-and-after design, one involving 
dietary cholesterol and four involving cafestol, and without data from three saturated fat trials 
with a parallel design. Again results were similar to the estimated differences when all trials 
were included. All analyses were performed with SAS statistical software (40). 
Results 
The baseline cholesterol levels (mean ± standard deviation) in the saturated fat trials 
were significantly smaller in men (4.88 ± 0.93 mmol/L) than in women (5.12 ± 0.89; P=0.03) 
(Table 2.2). 
Two-factor regression model 
Nevertheless, the adjusted responses of serum total cholesterol and LDL-cholesterol 
to saturated fat were larger in men than in women; the difference was 0.14 ± 0.05 mmol/L 
(mean ± standard error) for total cholesterol (95% confidence interval (CI), 0.04 to 0.23 
mmol/ L) and 0.08 + 0.04 mmol/L for LDL-cholesterol (95% CI, 0 to 0.17 mmol/L) (Figure 
2.2, Table 2.3). 
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mmol/L 
-0.70 ^ 
Total LDL HDL 
Cholesterol Response 
Figure 2.2 Adjusted responses of serum total, low-density lipoprotein (LDL-), and high-density 
lipoprotein (HDL-) cholesterol in men (N=126) and women (N=147) when nine energy percent 
dietary saturated fat was replaced by mono- or polyunsaturated fat, or carbohydrates. Responses 
were adjusted differences between trials in a two-factor model. Error bars indicate one standard 
error. * P < 0.05; ** P < 0.01 for differences between men and women. 
The adjusted response of total cholesterol to trans fat did not differ significantly 
between men and women, although both the decrease in LDL-cholesterol and the increase in 
HDL-cholesterol tended to be smaller in men than in women. The difference in response 
between men and women was -0.02 ± 0.06 mmol/L for LDL-cholesterol (95% CI, -0.13 to 
0.10 mmol/L), and 0.03 + 0.02 mmol/L for HDL-cholesterol (95% CI, -0.02 to 0.07 mmol/L). 
The adjusted response to dietary cholesterol was not significantly different for men 
and women. The difference in response between men and women was 0.01 ± 0.05 mmol/L for 
total cholesterol (95% CI, -0.08 to 0.11 mmol/L) and -0.01 ± 0.02 mmol/L for HDL-
cholesterol (95% CI, -0.05 to 0.02 mmol/L). 
The adjusted response of total cholesterol to cafestol was 0.22 ± 0.09 mmol/L larger in 
men than in women (95% CI, 0.04 to 0.39 mmol/L) and responses of LDL-cholesterol to 
cafestol were 0.22 ± 0.08 mmol/L larger in men than in women (95% CI, 0.06 to 0.37 
mmol/L) (Figure 2.3). 
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mmol/L 
Total LDL HDL 
Cholesterol Response 
Figure 2.3 Adjusted responses of serum total, low-density lipoprotein (LDL-), and high-density 
lipoprotein (HDL-) cholesterol in men (N=72) and women (N=61) to a decrease in the intake of the 
coffee diterpene cafestol. All responses were adjusted for differences between trials in a two-factor 
model. Error bars indicate one standard error. * P < 0.05; ** P < 0.01 for differences between men 
and women. 
Multiple regression models 
In a multiple regression model we adjusted for trial, age, body mass index, and change 
in weight during the trial. This yielded differences between the sexes in response of 
cholesterol similar to those found with the two-factor model. One of the largest differences in 
results between the two models was the difference between men and women in response of 
total cholesterol to cafestol, which was 0.19 mmol/L in the multiple regression model as 
opposed to 0.22 mmol/L in the two-factor model. 
We excluded the eight trials in which baseline cholesterol was part of the response to 
estimate the difference in response between men and women after adjustment for trial, age, 
body mass index, change in weight during the trial, and baseline cholesterol level. This model 
yielded differences in response between men and women similar to those found with the two-
factor model. The largest difference in results between the two models was the difference 
between men and women in the response of LDL-cholesterol to saturated fat, which was 0.12 
mmol/L in the multiple regression model as opposed to 0.08 mmol/L in the two-factor model. 
Thus, different models of statistical analysis yielded similar results. 
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Discussion 
We found that healthy men have larger responses of total cholesterol and LDL-
cholesterol to dietary saturated fat and to the coffee diterpene cafestol than healthy women. 
Adjustment for age, body mass index, change in weight during the trial, and baseline 
cholesterol levels did not affect the difference in response of cholesterol between men and 
women. However, it may not be suitable to adjust sex differences in cholesterol response for 
baseline cholesterol level. Baseline cholesterol level may not be a confounder of the 
relationship between sex differences and cholesterol response as the cholesterol response may 
affect the cholesterol level instead of being affected by the level (39). Other factors that might 
affect the cholesterol response to diet are smoking, menstrual cycle, and use of oral 
contraceptives (41,42,43). The exclusion of all smokers from our analyses (19 % of all 
subjects) did not affect the results. Thus, smoking does not appear to be responsible for the 
sex difference in cholesterol response. Because most of the women were pre-menopausal, 
both the menstrual cycle and use of oral contraceptives might have affected the response of 
cholesterol. However, the women entered the trials at different points of their menstrual cycle. 
In this way, cyclic effects on response of cholesterol were averaged out and could not have 
affected the mean response observed in women as an aggregate. Also, sex differences in 
response of cholesterol were not affected when we excluded the 33 % of women who used 
oral contraceptives. 
Reports about sex differences in cholesterol response to diet have been contradictory. 
The saturated fat trials which we pooled comprised a much larger number of subjects (126 
men and 147 women) than previous studies (22 to 82 men and 22 to 57 women) (9-15). Also, 
our estimation of individual responses was improved because 78 subjects participated in 
several trials with saturated fat. This may explain why we were able to show a clear-cut effect 
of sex on cholesterol responses to saturated fat where others were not. 
The difference in response to trans fat between men and women was not significant 
and the responses of LDL- and HDL-cholesterol tended to be smaller in men than in women 
rather than larger as they were for saturated fat. This agrees with earlier observations that 
metabolic pathways for trans fat are different from those for saturated fat (44, 45). However, 
the results for trans fat must be interpreted with caution, because the mean cholesterol 
response in the trans fat trials was smaller and the number of participants was smaller than in 
the saturated fat trials. 
Some studies reported that subjects who have a large response to dietary fat also have 
a large response to dietary cholesterol (18, 46). However, we found no difference between 
men and women in cholesterol response to dietary cholesterol. Although both the response to 
dietary cholesterol and the number of participants in the dietary cholesterol trials were smaller 
31 
Chapter 2 
than in the saturated fat trials, the estimation of the response was improved by 77 subjects 
who participated in at least two trials with dietary cholesterol. Our results may suggest that 
saturated fat and dietary cholesterol affect cholesterol metabolism through different 
mechanisms. This is in line with observations that different genes seem to be involved in 
determining the responses to dietary fat and cholesterol, the apoprotein E genotype seems to 
affect the response to dietary fat but not to dietary cholesterol (47) and the apoprotein A4 360 
genotype seems to affect the response to dietary cholesterol (48,49). 
Responses of total cholesterol and LDL-cholesterol to cafestol were larger in men than 
in women, which is similar to the effects of saturated fat. Our observations agree with 
epidemiological observations that the effect on cholesterol levels of drinking more than nine 
cups of boiled coffee per day tends to be larger in men than in women (50). 
One possible explanation for the observed differences between men and women in 
response of cholesterol to the fat composition of the diet is that men had a larger energy intake 
and thus consumed more saturated fat when expressed in absolute amounts (grams) than 
women. To investigate this, we adjusted our analysis for the level of energy intake during the 
last four weeks of each trial in a subset of the saturated fat trials for which data on energy 
intake were available (19-23). The response of LDL-cholesterol to saturated fat was 0.08 
mmol/L larger in men than in women both without and after adjustment for energy intake. 
Thus the larger response in men was not due to their larger overall food intake. In the cafestol 
trials men and women received the same absolute amount of cafestol, irrespective of their 
energy intake. However, if the amount of cafestol was adjusted for the energy intake, 
differences in cholesterol response between men and women would become even larger. 
It could be argued that women complied less with the diets than men, and as a result 
showed a smaller change in serum cholesterol. However, all subjects were highly motivated 
and conscious of the aim of the trial. In the controlled dietary trials, subjects received 90 
percent of all foods, and women as well as men consumed the hot meals under supervision. 
Also, adherence to the diets according to anonymous questionnaires was similarly high for 
women and men (19-23). Thus, we do not have any reason to believe that women were less 
compliant than men. Nevertheless changes in fatty acid composition of cholesterol esters 
following changes in the intake of saturated and trans fat were smaller in women than in men 
(unpublished observations). This might at first sight suggest that women were less compliant 
than men. However, it is also possible that differences between men and women in changes in 
fatty acid composition of cholesterol esters were caused by the same metabolic processes that 
caused differences in the responses of serum cholesterol. 
Animal studies support the notion that sex hormones affect the response of serum 
cholesterol to diet. Thus diets high in saturated fat and dietary cholesterol raised serum 
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cholesterol levels in male, but not in female hamsters. When the females were sterilized, their 
serum cholesterol became as responsive to diet as that of the male hamsters (51). 
The present findings are based on lean and healthy subjects with normal cholesterol 
levels. It is unknown whether they also apply to elderly, more obese, or hypercholesterolemic 
subjects. 
Our results imply that men will benefit more from a reduction in the intake of 
saturated fat than women. Nevertheless, the responses of women to reductions in the intake of 
saturated fat are still considerable. Therefore, dietary treatment should still be recommended 
for both men and women with hypercholesterolemia. 
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Apoprotein E genotype and the response of 
serum cholesterol to dietary fat, cholesterol, 
and cafestol 
Rianne M. Weggemans, Peter L. Zock, Jose M. Ordovas, Juan Pedro-Botet, Martijn B. Katan 
Abstract- Previous studies on the effect of the apoprotein (APO) E polymorphism on the 
response of serum lipids to diet showed inconsistent results. 
We therefore studied the effect of the APOE polymorphism on responses of serum 
cholesterol and lipoproteins to various dietary treatments. To this end, we combined data on 
responses of serum cholesterol and lipoproteins to saturated fat, to trans fat, to dietary 
cholesterol, and to the coffee diterpene cafestol with newly obtained data on the APOE 
polymorphism in 395 mostly normolipidemic subjects. 
The responses of low-density lipoprotein (LDL-) cholesterol to saturated fat were 0.08 
mmol/L larger in subjects with the APOE3/4 or E4/4 genotype than in those with the 
APOE3/3 genotype (95% confidence interval -0.01 to 0.18 mmol/L). In contrast, responses of 
LDL-cholesterol to cafestol were 0.11 mmol/L smaller in subjects with the APOE3/4 or E4/4 
genotype than in those with the APOE3/3 genotype (95% confidence interval -0.29 to 0.07 
mmol/L). Responses to dietary cholesterol and trans fat did not differ between subjects with 
the various APOE genotypes. 
In conclusion, the APOE genotype may affect the response of serum cholesterol to 
dietary saturated fat and cafestol in opposite directions. However, the effects are small. 
Therefore, knowledge of the APOE genotype by itself may be of little use in the identification 
of subjects who respond to diet. 
Atherosclerosis, in press 
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Introduction 
The response of serum cholesterol to changes in the diet varies considerably between 
subjects. Within subjects, this response to diet is to some extent reproducible (1) and may in 
part be an innate characteristic. Identification of genetic factors that affect the response may 
help to select an effective therapeutic approach for individual patients with an atherogenic 
lipid profile. 
Variation in one candidate genetic factor, the apoprotein E (APOE) gene, is known as 
the APOE polymorphism (2). The common allele of the APOE gene is the s3-allele, which 
encodes for cysteine at amino acid residue 112 and for arginine at residue 158. The s4-allele 
encodes for arginine at both residues and the e2-allele encodes for cysteine at both residues. 
The various ApoE isoforms differ in binding affinity for the LDL-receptor and the LDL-
receptor related protein, for high-density lipoprotein (HDL-) cholesterol, and for triglyceride-
rich particles (3-6). In industrialized societies, carriers of the e4-allele have the highest levels 
of serum total cholesterol and low-density lipoprotein (LDL-) cholesterol, carriers of the E3-
allele have intermediate, and carriers of the s2-allele have the lowest levels (3). In addition, 
subjects with the various APOE genotypes differ in the absorption efficiency of cholesterol 
from the intestine, in the synthesis rates of cholesterol and bile acids, and in the production of 
LDL apoprotein B (7-9). This suggests that also the response of serum cholesterol to diet may 
be affected by the APOE polymorphism. 
Some studies show that subjects with an s4-allele are more responsive to changes in 
the amount of dietary cholesterol (10-13), the fat composition (13-16), or the amount of 
dietary cholesterol and fat (8,17-22) than those without an s4-allele. However, other studies 
did not find a difference in responsiveness between subjects with an £4-allele and those 
without (23-36). 
There are several explanations for these contradictory results. One is that most of the 
studies lacked sufficient power to detect an effect of the APOE polymorphism on the response 
of cholesterol due to a small number of subjects. Some other explanations are that the APOE 
polymorphism affects the response of cholesterol in men only and not in women, or only in 
populations, in which baseline levels of serum total cholesterol and LDL-cholesterol differ 
between the various APOE genotypes. Yet, another explanation is that the APOE 
polymorphism may only affect the responses of serum cholesterol to specific changes in 
dietary cholesterol, dietary fat, or both. 
We therefore studied the effect of the APOE polymorphism on the response of serum 
cholesterol to the exchange of saturated fat for cw-unsaturated fat or carbohydrates, to the 
exchange of trans fat for cw-unsaturated fat, to supplementation with dietary cholesterol, and 
to supplementation with the coffee diterpene cafestol in 201 men and 194 women. 
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Chapter 3 
Materials and methods 
Subjects 
Our department has performed 26 controlled trials on diet and blood lipids with a total 
of 670 subjects between 1976 and 1996. Details about the design and methods of these trials 
are described elsewhere (37). The data of these trials have been carefully maintained. 
Therefore, we were able to pool the data and to calculate individual responses as well as mean 
responses of treatment groups. These mean responses agreed with those published at the time 
trials were done, showing that our data retrieval and cleanup had been successful. At the time 
of the trials, no DNA samples were collected. In order to obtain DNA samples, we traced the 
former participants in 1996 and 1997 and managed to find 609 of them. The protocol of the 
present study, which was approved of by the Ethical Committee of Wageningen Agricultural 
University, was explained to them. We obtained informed consent and collected DNA of 549 
subjects. We sampled blood from 486 subjects and collected mouth swabs from the other 63 
In the present study, we used data on 395 subjects, 113 of whom had participated in two trials 
with a different treatment (e.g. saturated fat and cafestol) and 8 of whom had participated in 
three trials with a different treatment. Thus, our data consisted of 775 responses to the various 
treatments in a total of 201 men and 194 women (Figure 3.1). At the time of the trials the 
subjects were healthy as indicated by a medical questionnaire, and by the absence of anemia, 
glucosuria, and proteinuria. 
Characteristics of trials 
All trials were designed to study responses of serum cholesterol to changes in the diet 
and had been approved by the appropriate medical ethical committees. We pooled data on 
response of serum cholesterol to saturated fat of seven trials, to trans fat of two trials, to 
dietary cholesterol of eight trials, and to the coffee diterpenes cafestol and kahweol of nine 
trials. These diterpenes are the substances that are responsible for the cholesterol-raising effect 
of unfiltered coffee, such as Scandinavian-style boiled coffee, Turkish coffee, and cafetiere 
coffee (38). Seven trials had a crossover design, 14 a parallel design with a control group, and 
five a before-and-after or linear design without a control group. The number of participants 
per trial ranged from 3 to 94 (median was 23) and the duration of the treatment ranged from 
1.5 to 14 weeks (median was 3 weeks). 
Diets and supplements 
All food was supplied in the seven trials with saturated fat, in the two trials with trans 
fat, and in three of the trials with dietary cholesterol. In the saturated fat and trans fat trials, 
the saturated or trans fat was exchanged for an equal energy amount of mono- or 
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polyunsaturated fat, or, in one saturated fat trial, for carbohydrates. In the four trials of dietary 
cholesterol without complete food supply, subjects received eggs as a supplement during the 
treatment period and guidelines for a diet low in cholesterol during the control period. In one 
other trial of dietary cholesterol, subjects received all foods during the treatment period and 
received dietary guidelines during the control period. In the nine cafestol trials subjects 
received coffee, coffee grounds, coffee oil, or cafestol and kahweol as a supplement and 
consumed their habitual diet throughout the trial. The observed responses in the various trials 
agreed with those expected on the basis of the change in diet. This indicates that compliance 
was excellent in the trials. 
Available data 
Information on APOE genotype and responses of total cholesterol and HDL- and 
LDL-cholesterol to saturated fat was available for 214 subjects, to trans fat for 82 subjects, to 
dietary cholesterol for 108 subjects, and to cafestol for 120 subjects. We did not analyze 
responses of LDL-cholesterol to dietary cholesterol because data on LDL-cholesterol and 
APOE genotype were available for only 40 of the 108 subjects. 
For the present study we also used data on sex, age, body mass index, and change in 
weight during the trial, which we considered to be potential confounders of the relationship 
between response of cholesterol and APOE genotype (17,28,39-45). In addition, we used data 
on serum cholesterol levels, which were measured when subjects consumed their habitual 
diets (Table 3.1). 
Laboratory analyses 
Lab personnel were never aware of the subject's treatment. Serum cholesterol levels 
were determined in at least two serum samples per treatment, which were obtained on separate 
days. All sera from one subject were analyzed within the same run. The coefficient of 
variation within one run for control samples ranged from 0.7 to 2.9 %. In all trials accuracy 
was checked by the analysis of three serum pools of known value provided by the U.S. 
Centers for Disease Control (Atlanta, AG). The mean bias with regard to the target values of 
the Centers for Disease Control pools ranged from -2 % to 1.1 % for total cholesterol and 
from -3.2 % to 3.3 % for HDL-cholesterol. LDL-cholesterol was calculated by means of 
Friedewald's equation (46). 
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Table 3.1 Characteristics of the subjects with various apoprotein (APO)E genotypes in the trials 
with saturated and trans fat, dietary cholesterol, and cafestol. 
Saturated/at 
Men/Women 
Age (years) 
Cholesterol level on habitual diet (mmol/1) 
Trans fat 
Men/Women 
Age (years) 
Cholesterol level on habitual diet (mmol/1) 
Dietary cholesterol 
Men/Women 
Age (years) 
Cholesterol level on habitual diet (mmol/1) 
Cafestol 
Men/Women 
Age (years) 
Cholesterol level on habitual diet (mmol/1) 
APOE2/2 and 2/3 
15/16 
29+ 12 
4.54 ± 0.68 
5/8 
24 ± 7 
4.51 + 0.58 
12/6 
32 ± 11 
4.59 ± 0.94 
7/11 
28 ± 12 
4.40 ± 0.60 
APOE3/3 
60/70 
28+ 12 
5.09 ± 0.96 
18/28 
26 ± 10 
4.99 + 0.69 
29/33 
35 ± 14 
5.30 ± 0.87 
39/31 
24 + 6 
4.36 ± 1.06 
APOE3/4 and 4/4* 
24/25 
27+11 
5.13 ±0.94 
12/11 
22 + 3 
5.05 ±0.81 
15/8 
34 ± 12 
5.54+ 1.36 
15/14 
25 ±6 
4.39+ 1.07 
Subjects with the APOE2/4 genotype, four with a response to saturated fat, five with a response to dietary 
cholesterol, and three with a response to cafestol, were excluded. 
We isolated DNA from fresh blood and from mouth swabs by "salting-out" procedures 
(47-49). We used the method described by Hixson and Vernier (50) for assessment of the 
APOE genotype in 500 samples. Forty-nine other samples could not be amplified by the 
method of Hixson and Vernier (50). We succeeded in genotyping 30 of these 49 samples by 
another method, a mutagenically separated PCR as described by Rust et al (51). Two 
independent investigators interpreted all gels and, in case the interpretation differed, the 
APOE genotype was reanalyzed. We analyzed 35 DNA samples in duplicate to check the 
accuracy of both procedures for the analysis of the APOE genotype. The investigators who 
interpreted the gels did not know which samples were the duplicates. The APOE genotypes of 
all duplicate samples agreed. 
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Statistical methods 
In all trials we defined individual responses of cholesterol as the level of serum 
cholesterol at the end of the treatment that increased cholesterol minus the level either at the 
end of the treatment that lowered cholesterol, the placebo treatment, or the diet without the 
cafestol or cholesterol supplement. In crossover trials with three treatments, for instance a 
saturated, mono-unsaturated, and poly-unsaturated fat diet, we calculated one response to the 
substitution of mono-unsaturated for saturated fat and one response to the substitution of poly-
unsaturated for saturated fat. Because the cholesterol level on the saturated fat diet is used in 
the calculation of the two responses, these are dependent. This does not affect the validity of 
the estimate, but it may slightly affect the standard error and thus the P-value. 
In the crude analysis, we studied the effect of APOE genotype on response to each of 
the four treatments, irrespective of whether a subject participated in more than one trial with a 
similar treatment. We calculated the sum of the APOE-subscript and its correlation (Pearson 
product-moment correlation coefficient) with the response of cholesterol. 
In the adjusted analyses, we adjusted the response for subject and trial. We adjusted 
for subject because 41 % of the subjects in the saturated fat trials and 56% of the subjects in 
the dietary cholesterol trials participated in more than one trial with a similar treatment or in a 
crossover trial with three treatments (37) (Figure 3.1). We adjusted for trial because there 
were background differences between the trials in background diet, duration of treatment, and 
time of the year the trial was performed. If a trial consisted of more than one treatment, we 
created factors indicating each treatment within a trial. In additional analyses we also adjusted 
for the subject characteristics sex, age, body mass index, and change in weight, because these 
were potential confounders of the relationship between the APOE genotype and serum 
cholesterol response (17,28,39-44). Subjects with the APOE2/4 (N=13) genotype were 
excluded from the analyses. We tested the adjusted differences in response of cholesterol 
between subjects with the APOE2/2 or E2/3, E3/3, and E3/4 or E4/4 genotype by analysis of 
variance. In case of significant differences, group means were compared by Fisher's Least 
Significant Difference test for multiple comparisons. 
We also analyzed the data using various other regression models. We calculated the 
mean response of each individual over trials with a similar treatment and estimated 
differences in this mean response between subjects with the various APOE genotypes. In yet 
other models, we expressed the cholesterol response as the percentage change from the serum 
cholesterol level at the end of the control or baseline period. All these models yielded similar 
differences in response between the APOE genotype groups, which confirmed the robustness 
of the models presented here (52). 
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Results 
In our subjects the frequency of the s2 allele was 0.09, of the e3 allele 0.79, and of the 
s4 allele 0.13. The frequency distribution was similar to those observed in Dutch and other 
Caucasian populations (3,53). Baseline characteristics were similar for subjects with the 
APOE2/2 or E2/3, E3/3, and E3/4 or E4/4 genotype, except for levels of total cholesterol 
while subjects consumed their habitual diet, which was lowest in subjects with the APOE2/2 
or E2/3 and highest in those with APOE3/4 or E4/4 genotype (Table 3.1). The level of total 
cholesterol on the habitual diet was 4.54 ± 0.07 mmol/L (mean ± standard error) in subjects 
with the APOE2/2 or E2/3 genotype, 5.03 ± 0.04 mmol/L in subjects with the APOE3/3 
genotype, and 5.08 ± 0.07 mmol/L in those with APOE3/4 or E4/4 genotype. Mean body mass 
index was 22 kg/m2 and mean age was 25 years. The body weight of the subjects did not 
change significantly during the trials. 
The responses of LDL-cholesterol to saturated fat tended to be smallest in subjects 
with the APOE2/3 genotype and largest in those with the APOE3/4 or E4/4 genotype (Figure 
3.2). The correlation between the sum of APOE-subscripts and the response of LDL-
cholesterol was 0.06 (P=0.29). After adjustment for subject and trial the response of LDL-
cholesterol to saturated fat was 0.08 mmol/L larger in subjects with the APOE3/4 or 4/4 
genotype than in those with the APOE3/3 genotype (95% confidence interval (CI) -0.01 to 
0.18 mmol/L) and 0.10 larger than in those with the APOE2/3 genotype (95% CI -0.04 to 
0.24). 
In contrast, responses of LDL-cholesterol to cafestol tended to be largest in subjects 
with the E3/3 genotype and smallest in those with the APOE2/3 and those with the APOE3/4 
genotype (Figure 3.3). The trial-adjusted response of LDL-cholesterol to cafestol was 0.11 
mmol/1 smaller in subjects with the APOE2/3 genotype (95% CI -0.35 to 0.13 mmol/L) and in 
subjects with the APOE3/4 or 4/4 genotype (95% CI -0.29 to 0.07 mmol/L) than in those with 
the APOE3/3 genotype. Responses of HDL-cholesterol to cafestol were -0.07 mmol/L smaller 
in subjects with the APOE3/4 or 4/4 genotype than in those with the APOE3/3 genotype (95% 
CI -0.14 to 0 mmol/L) and the responses of HDL-cholesterol in subjects with the APOE2/3 
genotype were -0.05 mmol/L smaller than in those with the APOE3/3 genotype (95% CI -
0.14 to 0.04 mmol/L). Responses of HDL-cholesterol to saturated fat did not clearly differ 
between subjects with the various APOE genotypes, as was the case for responses of LDL-
and HDL-cholesterol to trans fat and to dietary cholesterol (Table 3.2). 
The differences in response of serum cholesterol between subjects with the various 
APOE genotypes remained similar after adjustment for each of the following factors sex, age, 
body mass index, and change in weight. 
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Figure 3.2 The mean response of low-density lipoprotein (LDL-)cholesterol to saturated fat in 
subjects with various apoprotein (APO)E-genotypes. Error bars indicate one standard error. 
Values of N indicate the number of subjects per genotype group. 
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Figure 3.3 The mean response of low-density lipoprotein (LDL-)cholesterol to cafestol in 
subjects with various apoprotein (APO)E-genotypes. Error bars indicate one standard error. 
Values of N indicate the number of subjects per genotype group. 
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APOE polymorphism and cholesterol response 
Some authors, however, suggest that the effect of the APOE polymorphism on 
response differs between men and women. We therefore also analyzed men and women 
separately. The effect of the APOE polymorphism on the response of LDL-cholesterol to 
saturated fat was similar in men and women. Responses of HDL-cholesterol to trans fat were 
-0.07 mmol/L smaller in men with the APOE3/4 or 4/4 genotype than in men with the 
APOE3/3 genotype (95% confidence interval -0.01 to -0.14 mmol/L). Responses of HDL to 
dietary cholesterol were -0.07 mmol/L smaller in men with the APOE3/4 or 4/4 genotype than 
in men with the APOE2/3 genotype (95% confidence interval -0.01 to -0.13 mmol/L). 
Responses of HDL-cholesterol to cafestol were 0.16 mmol/L larger in women with the 
APOE3/3 genotype than in women with the APOE3/4 or 4/4 genotype (95% confidence 
interval 0.04 to 0.28 mmol/L) (Table 3.2). 
Discussion 
The present study showed that normolipidemic subjects with the APOE3/4 or E4/4 
genotype tended to have a larger response of LDL-cholesterol to saturated fat than those with 
the APOE3/3 genotype. In contrast, they had similar responses to trans fat and dietary 
cholesterol and they tended to have a smaller response to cafestol. 
We pooled data of 26 trials in order to obtain a large number of subjects to study the 
relation between APOE genotype and response of cholesterol to specific dietary changes. We 
used rigorously standardized laboratory procedures and multiple measurements per subjects. 
The precision of the estimation of serum cholesterol response to saturated fat and dietary 
cholesterol was further improved in the subjects who participated in more than one trial with a 
similar treatment. The precision of the responses reported here is therefore higher than in 
many other trials. The total number of subjects in our study vastly exceeded that in other 
studies of the relation between APOE polymorphism and cholesterol response, and even the 
number of subjects per treatment, i.e. saturated fat or dietary cholesterol, was higher than in 
any other previous study. 
Factors such as a subject's sex and body mass index may affect the association 
between APOE genotype and response (17,28,39-43). However, results remained similar after 
adjustment for the subject's sex, age, body mass index, or change in weight. When we 
analyzed men and women separately, the effect of the APOE polymorphism on the response 
of HDL-cholesterol to various dietary treatments differed between men and women. However, 
the differences between men and women may be due to chance, because the examination of 
several subgroups will increase the risk of chance associations. 
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Table 3.3 The mean baseline level (+ standard error) of serum total cholesterol by apoprotein 
(APO)E genotype. 
APOE2/2 or 2/3 APOE3/3 APOE3/4 or 4/4 
mmol/L 
Saturated fat 4.06 + 0.15a 4.63 ± 0.07b 4.78 + 0.1 lb 
Trans fat 4.22 ± 0.21a 4.84 ± 0.15b 4.92 +0.18b 
Dietary cholesterol 4.57 ± 0.19a 5.33 ±0.1 lb 5.43 +0.18b 
Cafestol 4.43 ± 0.16a 4.62 + 0.09a 4.96 +0.14b 
Values with different fonts differ significantly (P<0.05). 
The baseline level was measured during the treatment that lowered serum cholesterol, the placebo treatment or 
the diet without the cafestol or cholesterol supplement. 
Some authors suggested that effects of the APOE polymorphism on response may be 
more pronounced when levels of baseline cholesterol differ between subjects with the various 
APOE genotypes. In the present study, levels of total cholesterol measured while subjects 
consumed their habitual diet (Table 3.1) and baseline levels of total cholesterol (Table 3.3) 
were lower in subjects with the APOE2/2 or E2/3 genotype and somewhat higher in subjects 
with the APOE3/4 or E4/4 genotype than in those with the APOE3/3 genotype. These 
differences between subjects with various APOE genotypes in levels of cholesterol mirrored 
the differences in responses of cholesterol to saturated fat, but not to trans fat, dietary 
cholesterol, or cafestol. It is possible that the differences in levels mainly reflect differences in 
response to the amount of saturated fat, because saturated fat has a larger effect on the level of 
serum cholesterol than the amount of dietary cholesterol, trans fat, or cafestol in the habitual 
or baseline diet. 
In other studies in which the amount of saturated fat was changed, subjects with the 
s4-allele had either larger (13-16), similar or lower (24,25,34,54) responses of serum 
cholesterol than those with the APOE3/3, E3/2, or E2/2 genotype. Only two of these studies 
had at least 10 subjects with an s2-allele (16,24). In one of these two studies, subjects with the 
s2-allele had a smaller response to changes in dietary fat than those with the APOE3/3 
genotype (16), whereas responses were similar or larger in the other (24) (Figure 3.4). Only 
four studies had at least 10 subjects with an s4-allele (13,16,24,34). Subjects with an s4-allele 
had a larger response than those with the APOE3/3 genotype in one study with 
normolipidemic men (16) and in one out of two studies with hyperlipidemic men and women 
(13), but they had a similar response in one study with normolipidemic men and women (24). 
It may be that the effect of the APOE polymorphism is easier to detect in men than in women, 
because men are more responsive to saturated fat than women (37). Results of the study of 
Sarkkinen et al (13) suggest that the response is larger in subjects with the APOE4/4 genotype 
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Dietary fat (number of subjects APOE2 / E3/3) 
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Dietary cholesterol 
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(13 / 48) 
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LDL-cholesterol response of APOE2 - E3/3 (mmol/L) 
Figure 3.4 The difference in response of low-density lipoprotein (LDL-)cholesterol to an increase 
in dietary fat and dietary cholesterol between subjects with the apoprotein (APO)E2/2 or 2/3 
genotype and those with the APOE3/3 genotype and 95% confidence intervals of the difference in 
response. 
a
 We used data on the response of total cholesterol to dietary cholesterol instead of LDL-
cholesterol, because of the small number of subjects with an LDL-cholesterol response. 
than in those with the APOE3/4 genotype (Figure 3.5). Thus, the data from the present study 
and those from previous studies indicate that the APOE2/3 genotype may not affect the 
response of LDL-cholesterol to a change in saturated fat, the APOE3/4 genotype slightly 
enhances the response, whereas the APOE4/4 genotype strongly enhances the response. 
In the present study, the response to a decrease in the amount of dietary cholesterol 
was not related to APOE genotype. One problem in studying dietary cholesterol is that its 
effect on serum cholesterol level is smaller than that of saturated fat (55). Therefore, one may 
need more subjects to show a possible effect of the APOE genotype on response of serum 
cholesterol to dietary cholesterol. Other studies either found subjects with the s4 allele to be 
more responsive to dietary cholesterol than subjects without the s4 allele (10,12,13,56), or that 
there were no differences (23,25,29,57). Only one study had at least 10 subjects with the s2-
allele and showed that subjects with the APOE2/3 genotype had a somewhat smaller response 
to dietary cholesterol than those with the APOE3/3 genotype (29)(Figure 3.4). Only three of 
these studies had at least 10 subjects with an e4-allele (13,23,29). None of the three studies 
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Figure 3.5 The difference in response of low-density lipoprotein (LDL-)cholesterol to an increase 
in dietary fat and dietary cholesterol between subjects with the apoprotein (APO)E3/4 or 4/4 
genotype and those with the APOE3/3 genotype and 95% confidence intervals of the difference in 
response. 
We used data on the response of total cholesterol to dietary cholesterol instead of LDL-
cholesterol, because of the small number of subjects with an LDL-cholesterol response. 
Martin et al did not report sufficient data to calculate a 95% confidence interval. 
found a significant difference in response between normo- and hyperlipidemic men and 
women with the APOE3/3 and 3/4 genotype. The study of Sarkkinen et al (13) also included 
subjects with the APOE4/4 genotype. These subjects had a significantly larger response than 
those with the APOE3/3 or 3/4 genotype (Figure 3.5). Because all studies that found an effect 
of the APOE polymorphism on response to dietary cholesterol were Finnish, the high 
prevalence of the e4-allele in Finland might be an explanation for the seemingly inconsistent 
results. Therefore, the small number of subjects with the APOE4/4 genotype (N=2) in the 
present study might explain the absence of any effect in the present study. Thus, despite the 
fact that we did not find any significant difference in response between the various APOE 
genotypes, the e4-allele may still enhance the response of LDL-cholesterol to a change in 
dietary cholesterol but only in subjects with the APOE4/4 genotype. 
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We did not find a clear effect of the APOE genotype on the response of serum 
cholesterol to trans fat. However, the relatively small effect of trans fat on serum total 
cholesterol and LDL-cholesterol might have obscured such an effect. 
The response of LDL-cholesterol to cafestol tended to be lower in subjects with the 84 
allele than in subjects with the APOE3/3 genotype. The response of LDL-cholesterol to a 
change in the intake of oat or wheat bran or to lipid-lowering drugs pravastatin and lovastatin 
was also smaller in subjects with the s4 allele than in those without the s4 allele (58-60). 
These findings confirm that cafestol raises LDL via pathways different from those for dietary 
cholesterol or fat (61). 
In the present study, we investigated the effect of the APOE polymorphism on the 
response of serum cholesterol by itself and not in combination with other genetic 
polymorphisms. It is possible that knowledge of the APOE polymorphism in combination 
with knowledge of other polymorphisms may be of use in the identification of subjects who 
respond to diet. At this regard, one study showed that the APOC3 SstI polymorphism affected 
the expression of hyperlipidemia in subjects with the APOE2/2 genotype (62). 
In conclusion, the APOE effects were small. In view of these results, knowledge of the 
APOE genotype by itself in individual patients with high cholesterol levels may be of little use 
in the selection of an effective therapeutic approach. 
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Associations between 10 genetic polymorphisms 
and the serum lipid response to dietary fat, 
cholesterol, and cafestol in humans 
Rianne M. Weggemans, Peter L. Zock, Jose M. Ordovas, 
Jennifer Ramos-Galluzzi, Martijn B. Katan 
Abstract- The response of serum cholesterol to diet may in part be an innate characteristic. 
However, previous studies on the effects of polymorphisms in candidate genes on response to 
dietary treatments were not always consistent and often involved a small number of subjects. 
We now studied the effect of 10 genetic polymorphisms on responses of serum 
cholesterol and lipoproteins to diet. To this end, we used data on responses of serum 
cholesterol to dietary saturated and trans fat, cholesterol, and the coffee diterpene cafestol as 
measured in 26 previous dietary trials. We combined these responses with newly obtained 
data on 10 genetic polymorphisms from 405 mostly normolipidemic former participants in 
these trials. 
The response of serum low density lipoprotein (LDL-) cholesterol to diet was 
somewhat smaller in subjects with the apoprotein (APO)A4 347-1/1 genotype than in those 
with the APOA4 347-2 allele and in subjects with the APOA4 360-2/2 genotype than in those 
with the APOA4 360-1 allele. Subjects with the cholesteryl ester transfer protein (CETP) 
Taqlb-l allele had smaller responses of high-density lipoprotein (HDL-)cholesterol to diet 
than those with the CETP TaqIb-2/2 genotype. The effects of the other seven candidate 
polymorphisms were either inconsistent with results in previous studies or need to be 
replicated in other studies. 
In conclusion, the APOA4 347 and 360 and CETP Taqlb polymorphisms may affect 
the response of serum cholesterol to diet. The effects, however, are small. Therefore, 
knowledge of these genotypes by themselves is of little use in the identification of subjects 
who do not benefit from dietary treatment. 
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Introduction 
The response of serum cholesterol to dietary changes is to some extent reproducible 
within a subject and varies considerably between subjects (1). Theoretically the response may 
be affected by polymorphisms in genes which encode proteins that play a role in the 
cholesterol metabolism. Identification of these genetic polymorphisms may be of help in the 
identification of hypercholesterolemic subjects who will or will not benefit from dietary 
treatment. It may also clarify the role of certain proteins in the cholesterol metabolism. 
Evidence is growing that variation at several loci affects lipid responses. The APOE 
polymorphism, which has been most extensively studied, may explain some of the variation in 
response. In addition, polymorphisms in the APOA1, APOA4, APOB, CETP and LPL genes 
may affect the response (as reviewed in (2-4)). However, in most instances the evidence for 
these relations is limited to few studies that vary in kind and duration of dietary treatment and 
in subject characteristics. Furthermore, the strength of these studies is often limited by the 
small number of subjects. 
We now studied in 405 subjects the relation between 10 genetic polymorphisms and 
the response of serum cholesterol and lipoproteins to dietary factors known to affect plasma 
lipoprotein levels. 
Methods 
Subjects 
Our department has performed 26 controlled trials on diet and blood lipids with a total 
of 670 subjects between 1976 and 1996 (1,5-21). The data of these trials have been carefully 
archived. Therefore, we were able to pool the data and to calculate individual responses as 
well as mean responses of treatment groups. These mean responses agreed with those 
published at the time trials were done, showing that our data retrieval and cleanup had been 
successful. At the time of the trials, no DNA samples were collected. In order to obtain DNA 
samples, we traced the former participants in 1996 and 1997 and managed to find 609 of 
them. Nineteen former participants were seriously ill or had died. We could not trace another 
42 subjects. The protocol of the present study, which was approved of by the Ethical 
Committee of Wageningen Agricultural University, was explained to the other 609 subjects. 
Sixty of the 609 subjects refused to participate. Of those 60, 16 did not want to participate 
because of the genetic aspect of the study, the other 44 because of various other reasons. We 
obtained informed consent and collected DNA of the remaining 549 subjects. We sampled 
blood from 486 subjects and collected mouth swabs from the other 63, because these 63 
subjects did not live in the Netherlands anymore or could not give blood for other reasons. We 
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excluded 144 subjects, who had only received a control diet or a placebo treatment. Of the 
remaining 405 subjects, 117 had participated in two trials with a different treatment (e.g. 
saturated fat and cafestol), and 8 had participated in three trials with a different treatment. In 
addition, 40 % of the subjects in the saturated fat trials participated in more than one saturated 
fat trial or in a cross-over trial with three treatments, from which two responses were 
calculated. This also held for 10 % of the subjects in the trans fat trials, 55 % of those in the 
dietary cholesterol trials, and 15 % of those in the cafestol trials. Thus, our data consisted of 
903 responses to the various treatments from a total of 206 men and 199 women. The mean 
age of the subjects was 29 ± 12 years (mean ± standard deviation), mean cholesterol level 
while subjects consumed their habitual diet was 4.95 ± 0.88 mmol/L, mean body mass index 
22 ± 3 kg/m2, and 19 % of the subjects were smokers. At the time of the trials the subjects 
were healthy as indicated by a medical questionnaire, and by the absence of anemia, 
glucosuria, and proteinuria. 
Characteristics of trials 
All trials were designed to study responses of serum cholesterol to changes in the diet 
and had been approved by the appropriate medical ethical committees. We pooled data on 
response of serum cholesterol to saturated fat of seven trials (5-11), to trans fat of two trials 
(9,10), to dietary cholesterol of eight trials (1,12-15), and to the coffee diterpenes cafestol and 
kahweol of nine trials (16-21). Seven trials had a cross-over design (6,9-11,20), 14 a parallel 
design with a control group (1,5,7,8,12,14,15,18,19,21), and five a before-and-after or linear 
design without a control group (13,16,17,19). The number of participants per trial ranged from 
3 to 94 (median was 23) and the duration of the treatment ranged from 1.5 to 14 weeks 
(median was 3 weeks). All trials are described in more detail elsewhere (22). 
Diets and supplements 
All food was supplied in the seven trials with saturated fat (5-11), in the two trials with 
trans fat (9,10), and in three of the eight trials with dietary cholesterol (1,12,14,15). In the 
saturated fat and trans fat trials, the saturated or trans fat was exchanged for an equal amount 
of energy as mono- or polyunsaturated fat, or, in one saturated fat trial, for carbohydrates. In 
the four trials on dietary cholesterol without complete food supply, subjects received eggs as a 
supplement during the treatment period and guidelines for a diet low in cholesterol during the 
control period (1,12-14). In one other trial on dietary cholesterol, subjects received all foods 
during the treatment period and received dietary guidelines during the control period (15). In 
the nine cafestol trials subjects received coffee, coffee grounds, coffee oil, or cafestol and 
kahweol as a supplement and consumed their habitual diet throughout the trial (16-21). 
59 
Genetic polymorphisms and cholesterol response 
Available data 
Information on genotype and responses of total cholesterol and HDL- and LDL-
cholesterol to saturated fat was available for 221 subjects, to trans fat for 86 subjects, to 
dietary cholesterol for 110 subjects, and to cafestol for 121 subjects. 
For the present analysis we also used data on sex, age, body mass index, and change in 
weight during the trial, which might affect the relation between response of cholesterol and 
genetic polymorphisms (23-32). In addition, we used data on serum cholesterol levels, which 
were measured when subjects consumed their habitual diets. 
Laboratory analyses 
Laboratory personnel were never aware of the subject's treatment. Serum cholesterol 
levels were determined in at least two serum samples per treatment, which were obtained on 
separate days. All sera from one subject were analyzed within the same run. The coefficient of 
variation within one run for control samples ranged from 0.7 to 2.9 %. In all trials accuracy 
was checked by the analysis of three serum pools of known value provided by the U.S. 
Centers for Disease Control (Atlanta, GA). The mean bias with regard to the target values of 
the Centers for Disease Control pools ranged from -2.0 % to 1.1 % for total cholesterol and 
from -3.2 % to 3.3 % for HDL cholesterol (1,5-21). LDL cholesterol was calculated using the 
Friedewald's equation (33). 
We isolated DNA from fresh blood and from mouth swabs by "salting-out" procedures 
(34-36). We used various methods for the assessment of the genotypes (Table 4.1) (37-48). 
Results of analyses on the effect of the APOE polymorphism on response have been published 
previously (49). Two investigators independently interpreted all gels and, in case the 
interpretation differed, the genotype was reanalyzed. We analyzed 35 DNA samples in 
duplicate to check accuracy of analytical procedures. The investigators who interpreted the 
gels did not know which samples were duplicates. The genotypes of all duplicate samples 
agreed. We labeled the most frequent allele of each polymorphism with " 1 " and the least 
frequent allele with "2". 
Statistical methods 
In all trials we defined individual responses of cholesterol as the level of serum 
cholesterol at the end of the treatment that increased cholesterol minus the level either at the 
end of the treatment that lowered cholesterol, the placebo treatment, or the diet without the 
cafestol or cholesterol supplement. In cross-over trials with three treatments, for instance a 
saturated, mono-unsaturated, and poly-unsaturated fat diet, we calculated one response to the 
substitution of mono-unsaturated for saturated fat and one response to the substitution of 
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poly-unsaturated for saturated fat. Because the cholesterol level on the saturated fat diet in this 
instance was used in the calculation of the two responses, these are dependent. This does not 
affect the validity of the estimate, but it may slightly affect the standard error and thus the P-
value. 
In the crude analysis, we studied the effect of each genotype on response to each of the 
four treatments, irrespective of whether a subject participated in more than one trial with a 
similar treatment. 
In the adjusted analyses, we adjusted the relation between genetic polymorphisms and 
responses to saturated fat and dietary cholesterol for potential confounders subject, trial, and 
APOE genotype and we adjusted the response to trans fat and cafestol for trial and APOE 
genotype. We adjusted for subject because 40 % of the subjects in the saturated fat trials and 
55 % of the subjects in the dietary cholesterol trials participated in more than one trial with a 
similar treatment or in a cross-over trial with three treatments (7,8,11). We adjusted for trial 
because there were background differences between the trials in background diet, duration of 
treatment and time of the year the trial was performed. If a trial consisted of more than one 
treatment, we created factors indicating each treatment within a trial. We also adjusted for 
APOE genotype, because the APOE genotype may affect the response to diet (50). In 
additional analyses we further adjusted for the subject characteristics age, body mass index, 
and change in weight, because these are potential confounders of the relation between the 
various genotypes and serum cholesterol response (27-32). We also analyzed interactions 
between the various genotypes and sex in relation to response, because some previous studies 
reported sex-specific effects of some of the genotypes on response (24-27). In case of 
significant interaction we performed the analyses for men and women separately. We tested 
differences in the response of serum cholesterol between subjects with various genotypes by 
analysis of variance. In case of significant differences, group means were compared by 
Fisher's Least Significant Difference test for multiple comparisons (51). 
Results 
Overall, serum LDL-cholesterol increased upon replacement of unsaturated fat for 
saturated fat by 0.46 ± 0.39 mmol/L (mean ± standard deviation), upon replacement of cis-
unsaturated fat for trans fat by 0.30 ± 0.32 mmol/L, upon addition of dietary cholesterol by 
0.31 ± 0.55 mmol/L, and upon suppletion of cafestol by 0.68 ± 0.50 mmol/L. The level of 
serum HDL-cholesterol increased in response to saturated fat by 0.04 ±0.16 mmol/L and to 
dietary cholesterol by 0.08 ±0.12 mmol/L, it decreased in response to trans fat by -0.13 ± 
0.11 mmol/L and to cafestol by -0.04 ±0.16 mmol/L. 
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For all polymorphisms, the genotype distributions were in accordance with Hardy-
Weinberg equilibrium and the rare allele frequencies were similar to those reported in other 
European Caucasian populations (Table 4.1). 
Saturated fat 
The response of total cholesterol to saturated fat was significantly affected by the 
APOA4 360 polymorphism, being the lowest in the three subjects with the 2/2 genotype 
(crude P and P after adjustment for subject, trial and APOE-genotype = 0.05). The small 
number of subjects with the APOA4 360-2/2 genotype, however, limit these results (Table 
4.2). In addition, the response of LDL-cholesterol was significantly influenced by the APOB 
EcoRI polymorphism, being lower in those with the APOB EcoRI-1/2 genotype than in those 
with the 1/1 genotype (crude P=0.03; adjusted P=0.05) and by the MTP -493 polymorphism, 
being larger in those with the 2/2 genotype than those with the 1 allele (crude P=0.08; 
adjusted P=0.04) (Table 4.3). 
The response of HDL-cholesterol to saturated fat was associated with three 
polymorphisms, the APOC3 SstI (crude P=0.11; adjusted P=0.04), CETP Taqlb (crude and 
adjusted P=0.04) and LPL447 (crude P=0.08; adjusted P=0.03). Subjects with APOC3 Sstl-
1/1, CETP TaqIb-2/2 and LPL 447-1/1 genotype were more responsive than those with the 
respective other genotypes (Table 4.4). 
Trans fat 
The effect of the APOB polymorphism on the response of LDL-cholesterol to trans fat 
was similar to that on its response to saturated fat, with those with the APOB EcoRI-1/1 
genotype tending to be more responsive than those with the 2 allele (crude P=0.12; adjusted 
P=0.05) (Table 4.3). 
Dietary cholesterol 
Determinants of the response of total cholesterol and LDL-cholesterol to dietary 
cholesterol were the CETP Taqlb and the FABP2 54 polymorphisms. Those with the CETP 
Taqlb-1/1 and 1/2 genotypes had smaller responses than those with the 2/2 genotype (total 
cholesterol response crude P=0.02; adjusted P=0.01; LDL-cholesterol response 1/1 vs 2/2 
crude P=0.03; adjusted P=0.03; 1/2 vs 2/2, crude P=0.06; adjusted P=0.01), whereas the 
response of total cholesterol was smaller in subjects with the FABP2 54-1/1 genotype than in 
those with the 1/2 genotype (crude P=0.05; adjusted P=0.01) but somewhat larger than in 
those with the 2/2 genotype (Tables 4.2 and 4.3). 
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Genetic polymorphisms and cholesterol response 
The response of HDL-cholesterol to dietary cholesterol was, like its response to 
saturated fat, somewhat larger in subjects with the APOC3 Sstl-l/l genotype than in those 
with the 2 allele (crude P=0.07; adjusted P=0.06)(Table 4.4). 
Cafestol 
The only polymorphism that affected the response of total cholesterol and LDL-
cholesterol to cafestol was the APOA1 83 polymorphism, subjects with the APOA1 83-1/1 
genotype had larger responses than those with the APOA1 83-1/2 genotype (crude P=0.01; 
adjusted P=0.01) (Tables 4.2 and 4.3). 
Confounding and effect modification 
The differences in response were not materially affected by adjustment for subject, 
trial, and APOE genotype. In addition, previous studies suggested that the effect of some 
genetic polymorphisms on the response to diet are sex-specific (24-27). However, most of the 
effects of the genetic polymorphisms on response were in the same direction in men and 
women, with the exception of the APOA4 347 and 360 and CETP Taqlb polymorphisms: The 
effect of the APOA4 347 polymorphism on response was larger in women than in men. In 
women with the 1/1 genotype the response of serum LDL-cholesterol to trans fat was -0.22 
mmol/L smaller than that in women with the 1/2 genotype (95% confidence interval (CI), 
-0.44 to 0 mmol/L), whereas in men, the difference in response to trans fat was 0.02 mmol/L 
(95% CI, -0.21 to 0.25 mmol/L) (P for interaction = 0.07). The difference in response of LDL-
cholesterol to cafestol was -0.38 mmol/L in women (95 % CI, -0.72 to -0.03 mmol/L) and 
0.09 mmol/L in men (95% CI, -0.14 to 0.32) (P for interaction = 0.008). 
The effect of the APOA4 360 polymorphism was opposite in men and women (P for 
interaction = 0.07), men with the APOA4 360-1/1 genotype had a 0.28 mmol/L larger 
response of total cholesterol to dietary cholesterol than men with the 1/2 polymorphism (95% 
CI, 0.03 to 0.53 mmol/L), whereas women with the 1/1 polymorphism had -0.14 smaller 
responses than women with the 1/2 polymorphism (95% CI, -0.43 to 0.14 mmol/L). 
The effect of the CETP Taqlb polymorphism on the response of total cholesterol and 
LDL-cholesterol to trans fat was limited to women (P for interaction = 0.05), the response of 
LDL-cholesterol was 0.39 mmol/L larger in women with the 1/1 genotype than in those with 
the 2/2 genotype (95% CI, 0.06 to 0.72), whereas in men the difference was -0.07 (95% CI, 
-0.34 to 0.20 mmol/L). 
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Discussion 
The present study shows that genetic polymorphisms may affect responses of serum 
lipids to various dietary changes in healthy humans. However, there was not one single 
genotype that largely determined a subject's lipid response to diet. 
Quality of the data 
We pooled data of 26 trials in order to obtain a large number of subjects to study the 
relation between genetic polymorphisms and response of cholesterol to specific dietary 
changes. We used rigorously standardized laboratory procedures and multiple measurements 
of cholesterol level per subject. The precision of the estimation of serum cholesterol response 
to saturated fat and dietary cholesterol was further improved in the subjects who participated 
in more than one trial with a similar treatment. The precision of the responses reported here is 
therefore higher than in many other trials. The total number of subjects in our study vastly 
exceeded that in other studies of the relation between genetic polymorphisms and cholesterol 
response, and even the number of subjects per treatment, i.e. saturated fat or dietary 
cholesterol, was higher than in any other previous study. 
Confounding and effect modification 
Subject characteristics such as body mass index, APOE genotype, and sex may affect 
the association between genetic polymorphisms and response (23,27-32). However, the 
present results were not materially affected by adjustment for age, body mass index, or change 
in weight. This might have been due to the narrow range in the distribution of these subject 
characteristics and does not rule out the possibility that these factors affect the relationship 
between genetic polymorphisms and response. Adjustment for APOE genotype did not affect 
the results. However, it may be that the APOE genotype, like possibly sex, does not act as a 
confounder but rather as an effect modifier of the relation between genetic polymorphisms and 
lipid response (52). If so, it is not appropriate to adjust for APOE genotype. However, analysis 
of effect modification by APOE genotype was not attainable, because of the small number of 
subjects within various sub-groups. When we analyzed men and women separately, the effect 
of the APOA4 347 and 360 and CETP polymorphisms were either opposite in men and 
women or limited to one of the two sexes. The differences between men and women, 
however, might have been due to chance, because the examination of several subgroups will 
increase the risk of chance associations. 
Genetic polymorphisms and cholesterol response 
Risk of chance findings 
Overall, the risk of chance findings is 5 % in the present study that involved four 
dietary treatments, ten polymorphisms and three serum lipid values. This means that six out of 
120 hypotheses tested might be false positive. To check that present results are not chance 
findings, we took into account the results of previous studies on response and on possible 
mechanisms by which the polymorphism affects the response. In addition, promising relations 
should be checked in dietary trials, which are designed to study the effect of a genetic 
polymorphism on the response of serum cholesterol to diet. 
APOA1 polymorphisms 
In the present study, there were no differences in response of serum LDL- and HDL-
cholesterol between subjects with the various APOA1 -75 genotypes, which is in line with 
three previous studies (53-55), but not with all (56,57). The APOA1 -75 polymorphism is 
situated in the promoter region of the APOA1 gene. Studies on its effect on the cholesterol 
metabolism are also inconsistent (58-63). Therefore, it may be that the APOA1 -75 
polymorphism does not directly affect the cholesterol response, but is in linkage 
disequilibrium with a functional mutation in the APOA1 or a nearby gene. 
One of the polymorphisms that is related to the APOA1 -75 polymorphism is the 
APOA1 83 polymorphism (64,65). We found that the response of total and LDL-cholesterol 
to cafestol was smaller in subjects with the APOA1 83 1/2 genotype than in those with the 1/1 
genotype. We do not know of any other study that related this polymorphism to the response 
to diet. The APOA1 83 polymorphism is located in the first intron. Therefore we cannot 
exclude the possibility that the APOA1 83 polymorphism is a marker of another functional 
mutation that possibly affects the LDL-cholesterol response. 
APOA 4 polymorphisms 
In the present study, the response of LDL-cholesterol in subjects with the APOA4 347-
2 allele was somewhat larger than in those with the 1/1 genotype. This effect was larger in 
women than in men. The overall effects are in the same direction as those in some other 
studies (66,67). In contrast, two other studies did not find any effect (68,69). The substitution 
of serine for threonine at position 347 of the apo-AIV produces changes in the secondary 
structure of the protein and a slight increase in hydrophilic profile in this position (70). 
However, the precise mechanism by which the APOA4 347 polymorphism may affect the 
response to diet is unknown. Thus, the APOA4 347-2 allele may, if anything, slightly enhance 
the response of LDL-cholesterol to diet. 
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In the present study, subjects with the AP0A4 360-1/2 genotype had only slightly 
smaller responses of LDL-cholesterol to saturated and trans fat and cafestol than those with 
the 1/1 genotype, whereas subjects with the 2/2 genotype, who were all women, had 
considerably smaller responses of LDL-cholesterol. However, the number of subjects with the 
2/2 genotype was very small. Furthermore, in our previous study the response to increased 
cholesterol intake of one man with the 2/2 genotype was similar to that of those with the other 
genotypes (71). The present differences in response between subjects with the 1/1 and 1/2 
genotype are in line with those observed in some of the previous studies (71,72), albeit that 
other studies found a larger effect (26,27,73), whereas again other studies found a small 
opposite effect (66,68). In the present study, men with the 1/2-genotype were less responsive 
to dietary cholesterol than men with the 1/1-genotype. This sex-specific effect was also found 
in several other studies (26,27) and may be an explanation for the inconsistent results between 
the study of McCombs et al (73) and our previous study (71). The apoA-IV-2 isoform has 
more a-helical structure, is more stable in solutions and is more hydrofobic than the apoA-IV-
1 isoform (70). Nevertheless, the mechanism by which the APOA4 360 polymorphism may 
affect the response in men is not known (39). In conclusion, the attenuating effect of the 
APOA4 A3 60-1/2 genotype on the cholesterol response to dietary cholesterol may be limited 
to men. 
APOB EcoRI polymorphism 
The response of LDL-cholesterol to diet was somewhat smaller in those with the 
APOB EcoRI-1/2 genotype than in those with the 1/1 and 2/2 genotype. In contrast with these 
findings, one extensive meta-analysis (74) showed that there were no differences between 
subjects with the APOB EcoRI-1/2 and 1/1 genotype, whereas subjects with the 2/2 genotype 
tended to have larger responses than those with the 1/1 genotype. One explanation for the 
opposite findings on the effect of the 2/2 genotype may be the small number of subjects with 
the APOB EcoRI-2/2 genotype in all studies. The APOB EcoRI polymorphism in exon 29 
changes the amino acid sequence, but its functional role is unclear (74-76). We conclude for 
the present that the APOB EcoRI polymorphism may not affect the lipid response to diet. 
APOC3 SstIpolymorphism 
In the present study, the response of HDL-cholesterol to saturated fat and dietary 
cholesterol was smaller in those with the APOC3 SstI-1/2 genotype than in those with the 1/1 
genotype. In contrast, one previous study found no effect of the APOC3 polymorphism on 
response of serum lipids (54). In addition, another showed that there were no differences 
between the genotypes in response of HDL-cholesterol whereas the LDL-cholesterol response 
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of subjects with the 1/2 genotype was smaller than that of subjects with the 1/1 genotype (77). 
The APOC3 SstI polymorphism is situated in the 3' non-coding region of the APOC3 gene 
and may be functional, but may also be neutral or act as a genetic marker for another 
functional polymorphism (78). Thus studies so far are inconsistent and provide no convincing 
evidence that the APOC3 SstI polymorphism affects the response. 
CETP Taqlb polymorphism 
The present study showed that the response of LDL-cholesterol is smaller in those 
with the CETP Taqlb-1/2 than in those with the 1/1 genotype. In one other study, the response 
of LDL-cholesterol to fat was also somewhat smaller in those with the 1/2 than in those with 
the 1/1 genotype (66). In the present study, subjects with the 2/2 genotype had a somewhat 
larger response of HDL-cholesterol than those with the 1/1 and 1/2 genotype. In contrast, one 
previous study found that the response of HDL-cholesterol in patients with Type I diabetes 
was larger in those with the 1/1 genotype than in those with the 1/2 genotype upon 
consumption of a lipid-lowering diet (79), whereas another did not find any difference (66). If 
we assume that a larger lipid response leads to a higher lipid level, then the present effect of 
the CETP Taqlb polymorphism on HDL-cholesterol response will be in line with its effect on 
HDL-cholesterol levels in previous studies (25,45,80-83). These studies, however, are 
inconsistent with regard to whether the effect of the polymorphism on the cholesterol 
metabolism is sex-specific (25,80,82,84). Because the CETP TaqlB mutation is situated in 
intron 1, it is unlikely that this mutation is functional. Thus, the CETP genotype may be a 
marker for a mutation that affects the responses of serum HDL-cholesterol and LDL-
cholesterol to dietary changes. One mutation that is in linkage disequilibrium with the CETP 
Taqlb polymorphism is a functional mutation in the promoter region of the CETP gene, 
CETP/-629 (85). 
FABP2 54 polymorphism 
The present study showed that subjects with the FABP2 54-1/2 genotype were more 
responsive and those with the 2/2 genotype less responsive than those with the 1/1 genotype. 
In contrast with the present findings, one study on the response of serum lipids to dietary fiber 
found that subjects with the 1/2 genotype were less responsive than those with the 1/1 
genotype (86). However, another study found no effect of the FABP2 54 polymorphism on the 
levels of serum lipids (87). The FABP2 54 polymorphism gives rise to a structural change in 
the protein and may be functional, because the binding affinity for long-chain fatty acids in 
vitro is larger for the 2-isoform than for the 1-isoform (46). Nevertheless, the mechanism by 
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which this difference may affect the response is still unclear. Thus, the present findings should 
first be confirmed in another study. 
LPL 447polymorphism 
In the present study, subjects with the LPL 447-2 allele had smaller responses of HDL-
cholesterol to saturated fat than those with the 1/1 genotype. In contrast, one other study did 
not find any effect on the HDL-cholesterol response to dietary fat, whereas the response of 
LDL-cholesterol was significantly larger in subjects with the 1/2 genotype than in those with 
the 1/1 genotype (66). Furthermore, other studies showed that subjects with the LPL 447-2 
allele had higher HDL-levels (88,89) than those with the 1/1 genotype. The polymorphism 
gives rise to a structural change in the protein and may be functional as the production of the 2 
isoform is greater than that of the 1 isoform, leading to higher levels of LPL activity (90). 
However, the present effect of the LPL 447 polymorphism on response of HDL-cholesterol 
may have been a chance finding. 
MTP -493 polymorphism 
We found that subjects with the MTP —493-2/2 genotype had a larger LDL-response to 
saturated fat than those with the 1 allele. However, the number of subjects with the 2/2 
genotype is small. We do not know of any other studies on the effect of this polymorphism on 
the response. Results of studies on the effect of the MTP polymorphism on the level of LDL-
cholesterol are inconsistent (48,91). Although the MTP -493 polymorphism, which is situated 
in the promoter region of the MTP gene, may be of functional importance because it regulates 
the transcriptional activity by influencing allele-specific binding of nuclear proteins (48), 
evidence of any effect of the MTP polymorphism on response is weak. 
Gene-gene interaction 
In the present study, we investigated the effect of 10 polymorphisms by themselves. 
Overall, the individual polymorphisms explained up to 8 % of the variation in response of 
LDL-cholesterol and up to 4 % of the variation in response of HDL-cholesterol. We did not 
assess interactions between genetic polymorphisms, except for the interaction with sex. It is 
likely that knowledge of gene-gene interaction is of additional use in the identification of 
subjects who do not respond to diet. 
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Extrapolation 
The subjects in the present study were mostly young and had normal or moderately 
elevated cholesterol levels. Therefore, we do not know whether the gene-diet interactions are 
similar in an older, hyperlipidemic population. 
In conclusion, the APOA4 347 and 360 and CETP Taqlb polymorphism may affect the 
response of serum cholesterol to diet in healthy humans. However, the effects were small. 
Therefore, information on each of these genotypes alone is not sufficient to predict an 
individual's response to dietary treatment. 
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The apoproteinA4 360-1/2 polymorphism and 
response of serum lipids to dietary cholesterol 
in humans 
Rianne M. Weggemans, Peter L. Zock, Saskia Meyboom, Harald Funke, Martijn B. Katan 
Abstract- The response of serum lipids to dietary changes is to some extent an innate 
characteristic. One candidate genetic factor that may affect the response of serum lipids to a 
change in cholesterol intake is variation in the apoproteinA4 gene, known as the APOA4 360-
1/2 or apoA-IVGln360His polymorphism. However, previous studies showed inconsistent 
results. 
We therefore fed 10 men and 23 women with the APOA4 360-1/1 genotype and 4 men 
and 13 women with the APOA4 360-1/2 or 2/2 genotype (carriers of the APOA4 360-2 allele) 
two diets high in saturated fat, one containing cholesterol at 12.4 mg/MJ, 136.4 mg/day, and 
one containing cholesterol at 86.2 mg/MJ, 948.2 mg/day. Each diet was supplied for 29 days 
in cross-over design. 
The mean response of serum low-density lipoprotein cholesterol was 0.44 mmol/L (17 
mg/dL) in both subjects with the APOA4 360-1/1 genotype and in subjects with the APOA4 
360-2 allele (95 % confidence interval (CI) of difference in response, -0.20 to 0.19 mmol/L (-
8 to 7 mg/dL)). The mean response of high-density lipoprotein cholesterol was also similar, 
0.10 mmol/L (4 mg/dL), in the two APOA4 360 genotype groups (95 % CI of difference in 
response, -0.07 to 0.08 mmol/L (-3 to 3 mg/dL)). 
Thus, the APOA4 360-1/2 polymorphism did not affect the response of serum lipids to 
a change in the intake of cholesterol in this group of healthy Dutch subjects who consumed a 
background diet high in saturated fat. Knowledge of the APOA4 360-1/2 polymorphism is 
probably not a generally applicable tool for the identification of subjects who respond to a 
change in cholesterol intake. 
J Lipid Res 2000; 41:1623-1628 
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Introduction 
The response of serum lipids to dietary cholesterol varies between subjects. In some 
subjects, the response of serum lipids to an increased cholesterol intake is considerable, 
whereas in others the response is small. The response to dietary cholesterol is to some extent 
reproducible within a subject and may be in part an innate characteristic of a subject (1). There 
are a large number of candidate genetic factors that may affect the response (2). Identification 
of these genetic factors may contribute to the development of new tests to predict whether a 
subject with high serum lipid levels will benefit from a diet low in cholesterol. This may 
contribute to a more efficient treatment of subjects with high serum lipid levels. In addition, 
knowledge of genetic factors that determine the response of serum lipids to diet will help to 
gain insight into the mechanisms by which diet affects serum lipid levels. 
One of the candidate genetic factors which may affect the response of serum lipids is 
the apoprotein (APO)A4 gene, which encodes the apoA-IV protein. ApoA-IV is synthesized 
in the intestine (3). While the precise function of apoA-IV is still unknown, some studies 
suggest that it plays a role in the absorption of dietary fat (4) and in the metabolism of high 
density lipoprotein (HDL-) cholesterol and triglyceride-rich particles. In vitro studies showed 
that apoA-IV activates lecithinexholesterol acyltransferase (5) and regulates the activity of 
cholesteryl ester transfer protein (6) and lipoprotein lipase (7). One polymorphism in the 
APOA4 360 gene, the APOA4 360-1/2 polymorphism, is caused by a G to T substitution in 
exon 3 of the gene, which causes the glutamine-to-histidine substitution at position 360 in the 
apoA-IV protein (8). The apoA-IV-2 isoform has more oc-helical structure, is more stable in 
solutions and is more hydrophobic than the apoA-IV-1 isoform. These distinctive features are 
associated with a higher affinity for phospholipid surfaces and increased catalytic efficiency of 
the lecithinexholesterol acyltransferase activation in vitro (9,10). In addition, carriers of the 
apoA-IV-2 isoform have lower activity of plasma cholesteryl ester transport protein, higher 
apoA-IV concentrations (11), and slower apoA-IV catabolic rate in vivo (12). 
Studies on the effect of the APOA4 360-1/2 polymorphism on the response of serum 
lipids to diet are not consistent. Some studies showed that the APOA4 360-2 allele attenuates 
the response of low density lipoprotein (LDL-) cholesterol to dietary cholesterol (13) or 
dietary cholesterol plus fat (14), whereas other studies did not show a difference between 
subjects with the APOA4 360-1/1 genotype and those with the APOA4 360-2 allele in terms 
of response of LDL-cholesterol to dietary cholesterol plus fat (15,16) or to dietary fat (17). 
These results may indicate that the APOA4 360-1/2 polymorphism affects the response of 
serum LDL-cholesterol to dietary cholesterol, but not to dietary fat. 
We therefore tested the effect of the APOA4 360-1/2 polymorphism on the response of 
serum LDL-cholesterol to dietary cholesterol in a controlled experiment. 
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Methods 
Subjects 
The Ethics Committee of the Division of Human Nutrition and Epidemiology 
(Wageningen University, Wageningen, The Netherlands) approved of the study protocol. We 
recruited 200 subjects through advertisements in local newspapers and university and public 
buildings. We explained the aims and protocol of the study to the subjects. All subjects gave 
their written informed consent. We screened the subjects, mostly students living in or near the 
city of Wageningen, for the APOA4 360-1/2 polymorphism and identified 24 carriers of the 
APOA4 360-2 allele. We selected these 24 carriers and 47 subjects with the APOA4 360-1/1 
genotype for a medical screening. The medical screening consisted of a medical questionnaire, 
hemocytometry, and the assessment of triglycerides and total cholesterol in serum and of 
protein and glucose in urine after a 12-hours fast. We excluded one subject with serum 
triglyceride levels over 3.0 mmol/L, two subjects with disease of the gastro-instestinal tract, 
one subject with glucosuria and two subjects with proteinuria. All other subjects were 
apparently healthy, as indicated by the medical questionnaire. None of them had anemia, 
glucosuria, or proteinuria and none were taking medications known to affect blood lipids. 
During the period between the medical screening and the beginning of the dietary trial, 13 
subjects withdrew. Nineteen carriers of the APOA4 360-2 allele and 33 subjects with the 
APOA4 360-1/1 genotype started the dietary trial. Two carriers of the APOA4 360-2 allele 
dropped out during the dietary trial, one for personal reasons and one because of appendicitis. 
Seventeen carriers of the APOA4 360-2 allele, 16 Caucasians and one Hispanic, and 33 
subjects homozygous for the APOA4 360-1 allele, 32 Caucasians and one Hispanic, 
completed the dietary trial (Table 5.1). 
The two genotype groups had similar baseline characteristics, except that the APOE4-
allele and APOA4 347-T allele were more common in subjects with the APOA4 360-1/1 
genotype than in those with the APOA4 360-2 allele (Table 5.2). All subjects who completed 
the dietary trial received a financial reward. 
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Table 5.1 Selection of subjects with the apoprotein (APO) A4 360-1/1 genotype 
and carriers of the APOA4 360-2 allele. 
APOA4 360-1/1 APOA4 360-1/2 or 2/2 
Subjects recruited 176 24 
Excluded after genetic screening 
Excluded after medical screening* 
Withdrawal before the trial 
Subjects entering the trial 
Drop out during the trial 
Subjects finishing the trial 
The medical screening consisted of a medical questionnaire, hemocytometry, and the 
assessment of triglycerides and total cholesterol in serum and of protein and glucose 
in urine after a 12-hours fast. 
Design 
The dietary trial was designed to detect a significant difference (P<0.05) in response of 
LDL-cholesterol between subjects with the APOA4 360-1/1 genotype and subjects with the 
APOA4 360-2 allele with a power of 80 % if the real population effect exceeded 0.27 mmol/L 
(10 mg/dL). This power calculation was based on a within-subject standard deviation of 0.27 
mmol/L (10 mg/dL). In other studies at our laboratory, within-subject standard deviation was 
0.35 mmol/L (13 mg/dL) (18). We expected that the four blood collections per period, instead 
of two, would decrease the within-subject standard deviation by about 0.08 mmol/L (3 mg/dL) 
(19). 
The dietary trial consisted of two periods of 29 days, during which each subject 
consumed the diet low in cholesterol and the diet high in cholesterol in cross-over design (20). 
We included a 6-day wash-out period between the two periods (Figure 5.1). 
One group of 26 subjects (18 APOA4 360-1/1, 8 APOA4 3601/2 or 2/2; 7 men,19 
women) first received a diet low in cholesterol and then a diet high in cholesterol, the other 
group of 24 subjects (15 APOA4 360-1/1, 9 APOA4 3601/2 or 2/2; 7 men, 17 women) 
received the diets in reverse order. All subjects participated simultaneously. None the subjects 
and staff, except for one investigator (RMW), were aware of the APOA4 360 and 347 and 
APOE genotypes. 
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Table 5.2 Baseline characteristics of the subjects with the APOA4 360-1/1 genotype and carriers 
oftheAPOA4 360-2 allele. 
Men/Women (N) 
Age (years) 
Body mass index (kg/m2) 
Total cholesterol (mmol/L)f 
Triglycerides (mmol/L) i 
Smokers (N) 
Users of oral contraceptives (N of women) 
APOE genotype (N) 
E2/2 
E3/2 
E3/3 
E4/2 
E4/3 
APOA4 347 genotype (N) 
A/A 
A/T 
T/T 
APOA4 360-1/1 
10/23 
24 ± 9 
23 ± 2 
4.8 + 0.9 
1.1+0.4 
2 
9 
1 
3 
22 
1 
6 
18 
12 
3 
APOA4 360-1/2 or 2/2* 
4 / 1 3 
24 ±13 
22 ± 3 
4.6 + 0.8 
1.1 ±0.4 
3 
6 
0 
4 
12 
1 
0 
13 
4 
0 
' The subject with the APOA4 360-2/2 genotype was a man with the APOA4 347-A/T genotype and the 
APOE2/4 genotype . f To convert serum lipid values from mmol/L to mg/dL multiply mmol/L by 38.67. * To 
convert serum triglyceride values from mmol/L to mg/dL multiply mmol/L by 88.54. 
Week 0 1 2 3 4 5 6 7 8 9 
Screening 
High cholesterol diet 
Low cholesterol diet 
Wash 
-out 
Low cholesterol diet 
High cholesterol diet 
Blood collection I MM tttt 
Figure 5.1 Design of the controlled dietary trial. 
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Diets 
Before the trial, the habitual energy intake of the subjects was estimated by a food-
frequency questionnaire (21,22). The study diets were formulated at 18 levels of energy 
intake, ranging from 7 to 24 MJ/day, so that each subject received a diet that met his or her 
energy needs. Body weights were recorded twice per week and, if necessary, energy intake 
was adjusted to maintain a stable weight. 
The diets consisted of conventional foods and 29 different menus were provided over 
the course of each period. The nutrient composition of the low and high cholesterol diet was 
similar, except for dietary cholesterol (Table 5.3). 
Table 5.3 Composition of the low-cholesterol diet and of the high-cholesterol diet. 
Energy (MJ per day) 
Protein (% of energy) 
Fat (% of energy) 
Saturated fat 
Monounsaturated fat 
Polyunsaturated fat 
Carbohydrates (% of energy) 
Alcohol (% of energy) 
Cholesterol (mg/MJ) 
Cholesterol (mg/day) 
Fiber (g/MJ) 
Fiber (g/day) 
Low cholesterol diet 
11 
14.9 
37.8 
16.7 
11.1 
7.7 
46.2 
1.3 
12.4 
136.4 
3.0 
33.0 
High cholesterol diet 
11 
15.4 
39.6 
17.5 
11.7 
8.2 
43.8 
1.3 
86.2 
948.2 
3.1 
34.1 
Dietary cholesterol was added in the form of eggs and egg yolk powder. The egg yolk 
powder was used for baking bread and preparing salad dressings and deserts. Egg white 
powder and groundnut oil were used in the diet low in cholesterol to adjust for the added fat 
and protein from eggs and egg yolk powder in the high-cholesterol diet. Because the response 
of serum lipids to dietary cholesterol may be enhanced by a background diet high in saturated 
fat (23-25), both diets were high in saturated fat. 
All food items were weighed or counted out for each subject. On weekdays at noon, 
hot meals were served and consumed in the dining room for metabolic studies of the Division. 
All other food was supplied daily as a package. Food for the weekend and guidelines for its 
preparation were provided on Fridays. Approximately 90 % of the energy intake was from 
supplied foods, the remaining 10 % was from foods chosen by the subjects from a list of 'free-
choice' food items without cholesterol or fat. 
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Subjects were urged not to change their selection of the 'free-choice' food items 
throughout the study and not to change their smoking habits or physical activities. The 
participants kept diaries in which they recorded their daily selection of 'free-choice' food 
items, any sign of illness, medication used, phase of the menstrual cycle, and any deviations 
from their diets and the protocol. According to these diaries, adherence to the diets and 
protocol was excellent. 
Duplicate portions of each study diet were collected every day for an imaginary 
participant with a daily energy intake of 11 MJ, stored at -20 °C, and pooled and analyzed 
after the study. The energy and nutrient content of each subject's selection of the 'free-choice' 
food items were calculated and combined with the analyzed values of the duplicate portions. 
Blood collection and biochemical analyses 
All participants were assigned a random number that was used for labeling blood and 
serum tubes. In this way, the laboratory technicians did not know the subject's diet sequence 
or genotype. Blood samples were taken after a 12-hours fast on days 22, 24, 27 and 29 of each 
dietary period. We took a number of measures to reduce within-subject variation in serum 
cholesterol. Subjects remained standing while waiting for the blood collection. During the two 
dietary periods, venipunctures were performed by the same technicians, in the same location, 
at the same time of the same days of the week and with each subject always in the same 
position, which was either sitting or lying. Serum was obtained by low speed centrifugation 
between 0.5 to 1 hour after venipuncture, stored at -80 C, and analyzed enzymatically for 
total cholesterol, high-density lipoprotein (HDL-) cholesterol, and triglycerides (26). All 
samples from one subject were analyzed within the same run. The coefficient of variation 
within runs was 0.5 % for total cholesterol, 1.2 % for HDL-cholesterol, and 0.7 % for 
triglycerides. The mean bias with regard to target values of serum pools (Cholesterol 
Reference Method Laboratory Network) was -0.07 mmol/L (-3 mg/dL) for total cholesterol 
and -0.02 mmol/L (-1 mg/dL) for HDL-cholesterol. LDL-cholesterol was calculated (27). 
Genotyping 
DNA was isolated from fresh blood by a 'salting-out' procedure (28). The DNA was 
amplified for the assessment of the APOA4 360-1/2, APOA4 347-A/T and APOE2/3/4 
polymorphisms by mutagenically separated polymerase chain reactions (MS-PCR) (29). In 
each MS-PCR, the normal and mutant alleles were amplified in the same reaction tube, using 
allele-specific primers that differ in length. The MS-PCR-products were made visible by UV 
light on an agarose gel. We used 17 duplicate samples as a quality control measure for the 
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assessment of the genotypes. The investigators who assessed the genotypes did not know 
which samples were the duplicates. The genotypes of all 17 duplicate samples agreed. 
Statistical analyses 
The four values of serum lipids obtained for each subject at the end of each dietary 
period were averaged and then used for the calculation of the individual differences in serum 
lipid levels between the diets. Differences in response of serum lipids to dietary cholesterol 
between the subjects with the APOA4 360-1/1 genotype and subjects with the APOA4 360-2 
allele were analyzed by a two-tailed Student's t-test. We used the General Linear Models 
(GLM) procedure of the SAS program to check the effect of potential confounders, such as 
sex, body mass index, age, APOE2/3/4 polymorphism and APOA4 347-A/T polymorphism on 
differences in response between subjects with the various APOA4 360 genotypes (30). 
Results 
Overall, the switch from a diet low in cholesterol to a diet high in cholesterol increased 
levels of serum total cholesterol by 0.55 ± 0.32 mmol/L (21 ± 12 mg/dL) (mean ± standard 
deviation) or 12 %, levels of LDL-cholesterol by 0.44 ± 0.32 mmol/L (15 ± 12 mg/dL) or 17 
%, and levels of HDL-cholesterol by 0.10 ± 0.13 mmol/L (4 ± 5 mg/dL) or 6 %. 
The mean difference in response between subjects with the APOA4 360-1/1 genotype 
and subjects with the APOA4 360-2 allele was 0.01 mmol/L (0 mg/dL) for total cholesterol 
and HDL-cholesterol and 0 mmol/L (0 mg/dL) for LDL-cholesterol (Table 5.4). 
Adjustment for either sex, body mass index, age, baseline cholesterol level, change in 
body weight during the trial, APOE2/3/4 polymorphism, or APOA4 347-A/T polymorphism 
did not materially affect the difference in response of serum lipids between the APOA4 360 
genotype groups. The largest effect of adjustment was that for the APOE2/3/4 polymorphism; 
the adjusted response of LDL-cholesterol was 0.02 ± 0.09 mmol/L ( 1 + 3 mg/ dL) (estimated 
mean ± standard error) larger in subjects with the APOA4 360-1/1 genotype than in subjects 
with the APOA4 360-2 allele. 
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Table 5.4 Mean levels of serum total, low-density (LDL-) and high-density (HDL-) cholesterol 
(± standard deviation) during the low cholesterol and high cholesterol diets, difference in 
response, and its 95 % confidence interval (CI) in subjects with the apoprotein(APO)A4-l/l 
genotype (N=33) and carriers of the APOA4 360-2 allele (N=17). 
APOA4 360 
genotype 
Total cholesterol 
1/1 
1/2 or 2/2 
LDL-cholesterol 
1/1 
1/2 or 2/2 
HDL-cholesterol 
1/1 
1/2 or 2/2 
Low cholesterol diet 
4.53+0.84 
4.46 ± 0.57 
2.62 + 0.72 
2.54 ± 0.47 
1.5210.32 
1.52 + 0.20 
High cholesterol diet 
mmol/L* 
5.08 ± 0.97 
5.00 + 0.64 
3.06 ±0.85 
2.98 + 0.63 
1.63 + 0.33 
1.62 ±0.19 
Difference in response 
(95% CI) 
0.01 (-0.19 to 0.20) 
0.00 (-0.20 to 0.19) 
0.01 (-0.07 to 0.08) 
:
 To convert serum lipid values from mmol/L to mg/dL multiply values in mmol/L by 38.67. 
Discussion 
We found that the APOA4 360-1/2 polymorphism did not affect the response of serum 
lipids to an increased intake of cholesterol against a background diet high in saturated fat in 
Dutch subjects with normal cholesterol levels. The average response of serum total cholesterol 
to dietary cholesterol, 0.55 mmol/L (21 mg/dL), was in line with responses estimated from 
prediction equations (25,31,32). There were no significant differences between subjects with 
the APOA4 360-1/1 genotype and subjects with the APOA4 360-2 allele in the potentially 
confounding factors sex, body mass index, age, and baseline level of total cholesterol. In 
addition, the intake of total fat, fatty acids, and cholesterol during the trial was the same in the 
two groups, as was the average change in body weight. In the present study, however, the 
APOA4 347-T allele and APOE4-allele, which may enhance the response of serum lipids to 
diet (33-35), were more prevalent in subjects with the APOA4 360-1/1 genotype than in 
subjects with the APOA4 360-2 allele. However, this did not lead to a larger response in 
subjects with the APOA4 360-1/1 genotype than in those with the APOA4 360-2 allele. 
We did not assess other genetic polymorphisms than the APOA4 360-1/2 and 347-A/T 
and APOE-polymorphisms. Therefore, we cannot exclude the possibility that one of these 
other genetic polymorphisms biases our results. However, because most of these other 
candidate polymorphisms are not closely linked to the APOA4 360-1/2 polymorphism (2), the 
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various genotypes of these polymorphisms are likely to be randomly distributed over the 
subjects with the various APOA4 360 genotypes and may thus not bias the results of the 
present study. In addition, the APOA4 347-A/T polymorphism, which is linked to the APOA4 
360-1/2 polymorphism (36), did not bias the present results. 
In contrast with the present study, other studies found that the APOA4 360-2 allele 
attenuated the response of serum LDL-cholesterol significantly (13,14) or not significantly 
(15,17), whereas one other study found that the APOA4 360-2 allele enhanced the response 
(16) (Figure 5.2) (data for the calculation of 95 % confidence intervals: personal 
communication with dr R.B. Weinberg and dr J.M. Ordovas, 1999). 
Reference 
McCombs et al 1994 
Mata et al 1994 
Schaefer et al 1997 
Jansen et al 1997 
Jansen et al 1997 
Carmena-Ramon et al 1998 
Present study 
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A LDL-cholesterol response of APOA4 1/1 -1/2 or 2/2 
Figure 5.2 Differences in response of serum low density lipoprotein (LDL-) cholesterol to dietary 
cholesterol and/or fat between subjects with the apoprotein (APO) A4-1/1 genotype or ApoA-IV-
1/1 phenotype and subjects with the APOA4 360-2 allele or ApoA-IV-2 isoform and 95 % 
confidence intervals of the difference in LDL-cholesterol response in six studies. 
In the study of Mata et al (14) men with the apoA-IV-2 isoform had smaller responses 
of LDL-cholesterol to a decrease in the intake of cholesterol plus saturated fat than men with 
the apoA-IV-1/1 phenotype. In another study (15), which used in part some of the data of 
Mata et al (14), the differences between men with the various apoA-IV phenotypes were 
somewhat smaller. One explanation for the different findings in the study of Mata et al and the 
present study is that in the study of Mata et al not only the intake of cholesterol, but also the 
intake of fat was changed (14). This may indicate that the APOA4 360-1/2 polymorphism 
affects the response of LDL-cholesterol to a change in the intake of fat. However, people who 
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overrespond to dietary cholesterol also tend to overrespond to dietary fat (37). In addition, in a 
study of Jansen et al (17) responses of LDL-cholesterol were slightly smaller in men with the 
APOA4 360-2 allele than in men with the APOA4 360-1/1 genotype when carbohydrates were 
replaced by saturated fat or mono-unsaturated fat. Nonetheless, it remains possible that the 
APOA4 360-1/2 polymorphism affects the response of LDL-cholesterol to a change in the 
intake of both cholesterol and fat. 
Another explanation for the different findings are differences in subjects' 
characteristics. The subjects in the study of Mata et al (14) were middle-aged and moderately 
hyperlipemic, whereas the subjects in the present study were young and had normal 
cholesterol levels at baseline. However, responsiveness to dietary cholesterol does not differ 
between older and younger people (38), it is if anything more marked in people with higher 
cholesterol levels (39). In addition, in one study with subjects with familial 
hypercholesterolemia the response of serum LDL-cholesterol to an increased intake of 
cholesterol plus fat was not attenuated but somewhat enhanced by the APOA4 360-2 allele 
(16). It might be that the effect of mutations in the LDL-receptor on the response of 
cholesterol overshadowed the effects of the APOA4 360-1/2 polymorphism in these subjects. 
McCombs et al (13) showed that 11 young and normolipemic subjects with the apoA-
IV-2 isoform had a smaller response of LDL-cholesterol than 12 subjects with the apoA-IVl/1 
phenotype to an increased cholesterol intake. These results differed significantly from those in 
the present study (95% CI for difference in response 0.03 to 0.46 mmol/L (1 to 18 mg/dL)). 
A possible explanation for the difference in results between the studies of McCombs et 
al (13) and Mata et al (14) and the present study is that the APOA4 360-1/2 polymorphism 
affects the response of LDL-cholesterol in men only and not in women. In the study of 
McCombs et al (13), 74% of the subjects were men, whereas in the study of Mata et al (14) 
the APOA4 360-1/2 polymorphism affected the response in men, but not in women. In the 
present study, 28 % of the subjects were men and only four of them had the AP04-1/2 or 2/2 
genotype. Because of this small number we did not have sufficient power to analyze the 
effects of the APOA4 360-1/2 polymorphism in men only. The response of LDL-cholesterol 
was -0.04 ± 0.11 mmol/L (2 ± 4 mg/dL) (mean ± standard error) (P = 0.73) smaller in women 
with the APOA4 360-2 allele than in those with the APOA4 360-1/1 genotype, whereas it was 
0.17 ± 0.19 mmol/L (7 ± 7 mg/dL) (P = 0.39) larger in men with the APOA4 360-2 allele than 
in those with the APOA4 360-1/1 genotype. 
Another explanation for the difference in results is that we used a background diet 
high in saturated fat to enhance the response of serum cholesterol to dietary cholesterol. It is 
possible that the effect of the high saturated fat diet overwhelmed the effect of the APOA4 
360-1/2 polymorphism on cholesterol metabolism and response. However, we do not think 
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this is likely, because levels of total cholesterol on the low cholesterol, high saturated fat diet 
were still fairly low (mean 5.06 mmol/L (196 mg/dL)) and increased by 11% on addition of 
cholesterol to the high saturated fat diet. 
In the present controlled dietary trial the lipid response to dietary cholesterol was not 
affected by the APOA4 360-1/2 polymorphism in 37 women and 13 men with normal 
cholesterol levels, who were on a background diet high in saturated fat. This suggests that the 
APOA4 360-1/2 polymorphism may not be a generally applicable tool for the identification of 
subjects who respond to dietary cholesterol. 
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Dietary cholesterol from eggs increases the ratio 
of total cholesterol to high-density lipoprotein 
cholesterol in humans. A meta-analysis. 
Rianne M. Weggemans, Peter L. Zock, Martijn B. Katan 
Abstract- Several epidemiological studies did not find an effect of egg consumption on risk of 
coronary heart disease. It is possible that the adverse effect of dietary cholesterol from eggs on 
total and low-density lipoprotein cholesterol is offset by its favorable effect on high-density 
lipoprotein cholesterol. 
We reviewed the effect of dietary cholesterol on the ratio of total cholesterol to high-
density lipoprotein cholesterol, which is a more specific predictor of coronary heart disease 
than either lipid value alone. Studies were identified by MEDLINE and Biological Abstracts 
searches (1974- June 1999) and by reviewing reference lists. We added data from a study, 
which we recently published ourselves. Studies were included if they had a cross-over or 
parallel design with a control group, the experimental diets only differed in the amount of 
dietary cholesterol or eggs and were each fed for at least 14 days, and concentrations of high-
density lipoprotein cholesterol were reported. Of the 222 studies identified, 17 studies met 
these criteria. Extraction of data on design of the study, subject characteristics, composition 
and duration of the diets, and concentrations of serum lipids was done by the same 
investigator. 
The addition of 100 mg dietary cholesterol daily increased the ratio of total to high-
density lipoprotein cholesterol by 0.020 units (95% confidence interval (CI), 0.010 to 0.030), 
and the concentrations of total cholesterol by 0.056 mmol/L (2.2 mg/dL) (95% CI, 0.046 to 
0.065 mmol/L (1.8 to 2.5 mg/dL)) and of high-density lipoprotein cholesterol by 0.008 
mmol/L (0.3 mg/dL)(95% CI, 0.005 to 0.010 mmol/L (0.2 to 0.4 mg/dL)). 
In conclusion, dietary cholesterol raises the ratio of total cholesterol to high-density 
lipoprotein cholesterol and therefore adversely affects the cholesterol profile. The advice to 
limit the intake of cholesterol by reducing the consumption of eggs and other cholesterol-rich 
foods may therefore still be valid. 
Conditionally accepted 
Dietary cholesterol and blood lipids 
Introduction 
One of the dietary recommendations in the prevention of coronary heart disease is to 
limit the intake of eggs (1). The rationale behind this recommendation is that eggs are a major 
source of dietary cholesterol (2). Dietary cholesterol increases serum low-density lipoprotein 
(LDL-) cholesterol (3-5), an established risk factor for coronary heart disease (6). However, 
several epidemiological studies did not find a relation between egg consumption and the risk 
of coronary heart disease (7,8). The absence of a relationship may imply that the 
recommendation to lower egg consumption is only of little use in the prevention of coronary 
heart disease. One egg contains approximately 200 mg of cholesterol. Although it is obvious 
that dietary cholesterol increases concentrations of total cholesterol (3-5), several studies 
showed that dietary cholesterol increases not only concentrations of LDL-cholesterol but also 
concentrations of high-density lipoprotein (HDL-) cholesterol (3,4). As HDL-cholesterol may 
be protective against coronary heart disease, the adverse effects of dietary cholesterol on total 
cholesterol and LDL-cholesterol might be attenuated by the favorable effects on HDL-
cholesterol. 
The ratio of total cholesterol to HDL-cholesterol integrates the opposing effects on 
coronary heart disease risk of LDL- and HDL-cholesterol. As a result, it is a better predictor of 
the risk of coronary heart disease than the individual lipoprotein concentrations (6,9,10). 
Therefore, it may be more appropriate to study the effect of dietary cholesterol on the ratio of 
total cholesterol to HDL-cholesterol than on the individual lipoprotein concentrations. 
We now selected well-controlled studies to review the effect of dietary cholesterol 
from eggs on the ratio of total cholesterol to HDL-cholesterol in humans. We added data from 
a hitherto unpublished study of our own. 
Subjects and methods 
Selection of studies 
We screened MEDLINE (1974-June 1999) and Biological Abstracts (1989-June 1999) 
for experimental studies on the effects of dietary cholesterol and eggs on total cholesterol and 
lipoproteins. We did not screen MEDLINE before 1974 as measurements of HDL-cholesterol, 
which is part of our main outcome's measure, were not available at the time. For the literature 
searches, the key words egg, eggs, and dietary cholesterol were each intersected with the 
words serum (plasma) lipoprotein, serum (plasma) cholesterol, HDL, and LDL. We found 
1190 citations in MEDLINE and 883 in Biological Abstracts (Figure 6.1). In addition, we 
checked the reference lists of several meta-analyses (3-5,11,12) and selected studies. A scan of 
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Medline 
1190 articles 
Biological abstracts 
N=883 
Title scan 
Abstract scan 
Full-paper check 
221 articles 
56 articles 
_r 
16 selected articles 
1 additional abstract not in 
literature search 
19 articles for additional analysis 
' 
Reference lists 
_L 
21 articles not selected 
Figure 6.1 The selection of the articles for the meta-analysis and for the additional analysis. 
the titles led to the selection of 221 citations. The abstracts of these citations were examined 
for compliance with the following inclusion criteria. The studies had to be published in 
English. Within a study, the composition of the experimental diets should differ only in the 
amount of cholesterol or in the amount of eggs. The subjects should be weight stable 
throughout the study. The design had to eliminate the effect of nonspecific drifts of the 
outcome variable with time. This is accomplished by either feeding different groups of 
volunteers different diets side by side (parallel design) or feeding each volunteer several diets 
in random order (cross-over or Latin-square design). Studies with before-and-after designs or 
linear designs without a control group were excluded. The feeding periods had to last at least 
14 days, in order to attain equilibrium in concentrations of total cholesterol and lipoproteins. 
Further, studies had to report fasting concentrations of total cholesterol and lipoproteins. Of 
the 221 articles passing the title scan, 56 passed the abstract scan. Because most of the 56 
abstracts did not provide sufficient information on the selection criteria, we checked the full-
text of these articles. Sixteen of the 56 articles (28 %) met the inclusion criteria (13-28). Most 
other studies were not selected because they did not provide information on concentrations of 
HDL-cholesterol or had a linear design without a control group. In addition to the data of 
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Dietary cholesterol and blood lipids 
the 16 studies, we used data of our own study on the response to egg yolk cholesterol as a 
function of the apoprotein A-4 1/2 polymorphism, which was recently published (29) (Table 
6.1). 
The 17 studies yielded 24 dietary comparisons and 5 control treatments. The studies 
included 422 men and 134 women. Ten trials were carried out in men only, six included both 
men and women, and one study included women only. None of the studies reported the race of 
the subjects. The age of the volunteers ranged from 18 to 75 years, mean body mass index 
ranged from 20.8 to 28 kg/m2, and mean baseline cholesterol concentration ranged from 4.06 
to 5.92 mmol/L (157 to 229 mg/dL). Not all studies reported mean body mass index (13,15-
17,20,26) or baseline cholesterol concentration (20,21,25,28). Eleven were metabolic ward 
studies, in which all food was provided and five employed free-living subjects who were 
provided with eggs, high cholesterol products, or egg-free substitutes. The change in 
cholesterol intake ranged from 137 to 897 mg per day. Values for the concentrations of total 
cholesterol, LDL- and HDL-cholesterol in plasma were multiplied by 1.029 to convert them to 
serum values (30). 
Statistical analysis 
We subtracted the mean concentration of serum cholesterol at the end of the low-
cholesterol diet from that at the end of the high-cholesterol diet to calculate the change in 
serum cholesterol. Only six studies reported the means of individual ratios of total cholesterol 
to HDL-cholesterol (15,18,20,24,29,31) and only four studies reported the means of the 
individual ratios of HDL- to LDL-cholesterol (15,20,27,29). Therefore, we used mean 
concentrations in total, LDL- and HDL-cholesterol concentrations at the end of each diet to 
estimate the mean ratios of total cholesterol to HDL-cholesterol and HDL- to LDL-
cholesterol. According to the Taylor-approximation, this procedure to calculate the ratios 
caused an underestimation of the true ratio. The size of the underestimation is dependent on 
the total variation in the numerator and denominator and the correlation between the 
numerator (x) and denominator (y), E(x/y) « Ex/Ey * [1+CVy * {CVy - corr (x,y) * CVx}] 
(32). From an independent and large set of data (33), we calculated the coefficients of 
variation (CV) of total cholesterol, 0.21, HDL-cholesterol, 0.22, and LDL-cholesterol, 0.25, 
and the correlation coefficients of HDL-cholesterol with total cholesterol, 0.194, and with 
LDL-cholesterol, 0.195. Therefore, the ratio of mean total cholesterol to mean HDL-
cholesterol as used by us was approximately 4 % lower than the mean of the individual ratios, 
similarly the ratio of mean HDL- to mean LDL-cholesterol was approximately. 7 % lower. We 
assumed that the underestimation varied at random by treatment and study. This implies that 
the changes in ratios in the present study are marginally smaller than those obtained when the 
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mean change in individual ratios would be used. We did not adjust the ratios and their changes 
for this minute underestimation. 
For studies with a cross-over or latin-square design, the observed changes could be 
fully attributed to the change in dietary cholesterol or egg consumption, because the study 
design eliminates drift of variables over time. For studies with a parallel design, we adjusted 
for drift of variables over time by subtracting the changes in total cholesterol and lipoproteins 
in the control group from those in the treatment group. For instance in the study of Buzzard et 
al (14), total cholesterol concentrations increased by 0.27 mmol/L (10.4 mg/dL) in the 
treatment group and by 0.15 mmol/L (5.8 mg/dL) in the control group. We subtracted the 0.15 
mmol/L (5.8 mg/dL) from the 0.27 mmol/L (10.4 mg/dL) to obtain the actual increase in the 
treatment group, 0.12 mmol/L (4.6 mg/dL). 
Regression analysis 
We used linear regression models (General Linear Models procedure) (34) to study the 
effect of dietary cholesterol on total cholesterol and lipoproteins. We did not use any non-
linear regression models, because the number of studies in our data set was limited. Moreover, 
the present analysis comprised only three studies (15,20,21) with a cholesterol intake just over 
1000 mg per day, whereas the relation between cholesterol intake and cholesterol 
concentrations appears linear up to a cholesterol intake of 1000 mg per day (5). We applied 
several linear models. In one, the change in total cholesterol and lipoproteins (mmol/L) was 
expressed as a function of the absolute change in dietary cholesterol in mg per day. Regression 
lines were forced through the origin, because a zero change in cholesterol intake will by 
definition produce no change in lipoprotein cholesterol attributable to dietary cholesterol. 
Thus, we applied the following model 
Change in serum cholesterol = R x (Change in dietary cholesterol) 
The change in serum cholesterol is expressed in mmol/L for concentrations and in dimensionless 
units for ratios. The change in dietary cholesterol is expressed in units of 100 mg per day. 
We also expressed dietary cholesterol in milligram per megajoule (1 megajoule equals 
238 kilocalories). For these analyses, we excluded four studies, which did not provide data on 
energy intake (14,18,20,27). There were no large differences in the average energy intake 
between the various studies and the results did not materially alter when we expressed the 
dietary cholesterol in milligram per megajoule instead of milligram per day. Therefore, we 
only report the effects of a change in dietary cholesterol in milligram per day. 
Although studies were selected on the basis of the design and duration of the 
treatments, there were still considerable differences between the studies. The number of 
subjects per study ranged from 9 to 131. To take this into account, it is usual in meta-analyses 
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to weight each study by the reciprocal of the squared standard error. However, the standard 
errors of the changes in cholesterol and lipoprotein concentrations were not reported in some 
of the studies. We therefore weighted each study by the number of subjects, which is inversely 
proportional to the squared standard error. Further, the ratio of poly-unsaturated to saturated 
fat of the background diet varied between studies. A high ratio of poly-unsaturated to 
saturated fat, which is an indicator of a background diet relatively low in saturated fat, may 
attenuate the change in total cholesterol upon an increase in dietary cholesterol (5,35,36). In 
additional analyses we checked whether the ratio of poly-unsaturated to saturated fat affected 
the relation of dietary cholesterol with total cholesterol and lipoproteins. Analysis of the 
residuals was performed to check the appropriateness of each model. 
To detect publication bias, we explored heterogeneity in funnel plots visually. To this 
end, we plotted the response of serum lipids to 100 mg dietary cholesterol against the sample 
size by study. In the absence of bias, the plots will resemble a symmetrical inverted funnel, as 
results of small studies will scatter at the left side of the plot with the spread narrowing among 
larger studies on the right side of the plot (37). 
Results 
All 17 studies reported values for total cholesterol and HDL-cholesterol, but two 
studies did not report values for LDL-cholesterol (14,19) (Table 6.1). Most studies presented 
comparisons of two diets, but four studies presented comparisons of three or four diets 
(13,19,22,23). In two studies, various groups of subjects were studied side by side. In one 
study diabetics were compared with healthy subjects (27), whereas in another study 
hyperlipemic subjects were compared with combined-hyperlipemic subjects (28). 
The ratio of total cholesterol to HDL-cholesterol and the concentrations of total and 
LDL-cholesterol increased relative to control groups or treatments upon an increase in dietary 
cholesterol in all but one of the studies, whereas the concentrations of HDL-cholesterol 
increased in 19 of the 24 dietary comparisons. The ratio of HDL- to LDL-cholesterol 
decreased in all but one of the studies. 
If we assume that one egg contains 200 mg of cholesterol (2), consumption of one 
additional egg daily will increase the ratio of total cholesterol to HDL-cholesterol by 0.041 ± 
0.011 units (mean ± standard error of the estimate), the concentrations of total cholesterol by 
0.111 ± 0.010 mmol/L (4.3 ± 0.4 mg/dL), LDL-cholesterol by 0.100 ± 0.008 mmol/L (3.9 ± 
0.3 mg/dL), and HDL-cholesterol by 0.016 ± 0.003 mmol/L (0.6 ± 0.1 mg/dL) (Figure 6.2). 
One additional egg daily will decrease the ratio of HDL- to LDL-cholesterol by 0.011 ± 0.002 
units (Table 6.2). 
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Figure 6.2 Changes in serum LDL-cholesterol ( • ) and HDL-cholesterol (A) upon cholesterol 
feeding in 17 studies providing 24 dietary comparisons. 
Table 6.2 The predicted changes (± standard error of the estimate) in serum total cholesterol 
and lipoproteins induced by a 100 mg increase in dietary cholesterol and the 95 % confidence 
interval of the predicted change. 
Predicted change in serum cholesterol 100 mg/day increase in 
dietary cholesterol 
95% confidence interval 
Total cholesterol (mmol/L) 
HDL-cholesterol (mmol/L) 
LDL-cholesterol (mmol/L) 
Total/HDL-cholesterol 
HDL-/LDL-cholesterol 
0.056 + 0.005 
0.008 ± 0.001 
0.050 ± 0.004 
0.020 ± 0.005 
-0.006 ± 0.001 
0.046 to 0.065 
0.005 to 0.010 
0.042 to 0.058 
0.010 to 0.030 
-0.008 to -0.004 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
To convert serum lipid values from mmol per liter to mg per deciliter, divide mmol per liter by 0.02586. 
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Figure 6.3 The effect of a change in cholesterol intake on serum LDL-cholesterol in studies with 
a ratio of poly-unsaturated to saturated fat less than or equal to 0.7 (A) and more than 0.7 (D). 
We divided the studies into those with a ratio of poly-unsaturated to saturated fat less 
than or equal to the median, 0.7, indicative of a background diet relatively high in saturated fat 
and those more than 0.7, indicative of a background diet relatively low in saturated fat. The 
response of LDL-cholesterol to a change in dietary cholesterol was somewhat weaker in the 
studies with a background diet low in saturated fat than in those with a background diet high 
in saturated fat (Figure 6.3). We estimated that each additional 100 mg of dietary cholesterol 
will increase serum LDL-cholesterol by 0.036 ± 0.004 in the studies low in saturated fat and 
by 0.061 ± 0.006 in the studies high in saturated fat (P = 0.03). The fatty acid composition of 
the background diet did not affect the response to dietary cholesterol of HDL-cholesterol or of 
the ratio of total cholesterol to HDL-cholesterol or HDL- to LDL-cholesterol. 
We did not detect publication bias as indicated by the absence of heterogeneity in 
funnel plots (results not shown). 
We checked whether our results also applied to other studies. For this purpose, we 
selected 19 articles that did report concentrations of HDL-cholesterol but had failed to meet 
other inclusion criteria, such as the design (Figure 6.1). These 19 studies provided 33 dietary 
comparisons (36,38-55). In 20 out of these 33 dietary comparisons, the ratio of total 
cholesterol to HDL-cholesterol increased, whereas in the other 13 the ratio decreased when 
cholesterol intake increased. Regression analysis showed that a 100 mg per day increase in 
dietary cholesterol increased the ratio of total cholesterol to HDL-cholesterol by 0.014 ± 0.003 
units in these studies, whereas the increase was 0.020 units in the studies that fulfilled our 
selection criteria (Figure 6.4). 
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Figure 6.4 The effect of an increase in dietary cholesterol on the ratio of total cholesterol to 
HDL-cholesterol in 17 studies that fulfilled the selection criteria (A) and 19 studies that did not 
fulfill our selection criteria (D). 
Discussion 
Our meta-analyses of 17 trials showed that dietary cholesterol increased the ratio of 
total cholesterol to HDL-cholesterol. The effect was highly significant (P < 0.0009) and the 
95% confidence interval was narrow. This suggests that the favorable rise in HDL-cholesterol 
upon increased cholesterol intake fails to compensate for the adverse rise in total cholesterol 
and LDL-cholesterol and that therefore increased intake of dietary cholesterol may raise the 
risk of coronary heart disease. Our meta-analysis covered men and women from North 
America (13-18,20-23,26,28), Europe (24,25,27,29), and South Africa (19) with a wide range 
of ages. The consistency of the findings between studies suggests that our conclusions are 
valid for much of the white populations of affluent countries. However, the absence of data on 
the race of the subjects does not allow confident extrapolation to other populations. 
In the present study, we used a regression model without an intercept, because a zero 
change in cholesterol intake will by definition produce no change in serum cholesterol 
attributable to dietary cholesterol. However, in studies that change the intake of eggs, not only 
the intake of dietary cholesterol, but also the intake of other egg components such as fat and 
lecithin is changed. These factors may also affect concentrations of serum cholesterol and for 
such studies, it may therefore not be valid to force the regression line through the origin. To 
check this, we performed an analysis excluding studies that changed the intake of eggs 
(14,16,19,26) or that did not report whether the change in the intake of fat was adjusted for in 
the control diet (20,24). This did not materially alter the results and we therefore included 
these studies in our analysis. 
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Stratification of the studies for study design (cross-over or latin-square versus parallel) 
or for setting (metabolic ward versus free-living) or adjustment of the change in dietary 
cholesterol for energy intake did not materially alter the results. A high ratio of poly-
unsaturated to saturated fat, indicating a background diet relatively low in saturated fat, 
attenuated the change in LDL-cholesterol induced by an increase in dietary cholesterol. Some 
other studies also found that a background diet low in saturated fat attenuated the effect of 
dietary cholesterol on serum total cholesterol and LDL-cholesterol (35,36,56), whereas others 
did not (13,31,42,50,57-59). In some of the latter studies the change in dietary cholesterol 
might have been too small to show an effect of the fat-composition of the background diet on 
the change in serum cholesterol. The ratio of poly-unsaturated to saturated fat, however, does 
not take into account the absolute amount of fat in a diet. Thus, a diet with 5 energy percent 
poly-unsaturated fat and 10 energy percent saturated fat has the same ratio as a diet with 10 
energy percent poly-unsaturated fat and 20 energy percent saturated fat. Differences between 
studies in the absolute amount of fat may therefore be also be an explanation for some of the 
inconsistent results. 
We did not identify publication bias in our meta-analysis by use of funnel plots. In the 
studies that failed to fulfill our selection criteria the effect of dietary cholesterol on the ratio of 
total cholesterol to HDL-cholesterol was somewhat smaller than in those included in our 
meta-analysis. This might be due to lack of dietary control resulting in a larger error in the 
amount of dietary cholesterol that was changed. This attenuates the estimated effect of dietary 
cholesterol on serum cholesterol towards the null (60). However, it may also be due to the 
lack of adjustment for the change in fat intake that is induced by the change in egg 
consumption. Only three (40,46,49) of these 19 studies adjusted for the change in fat intake, 
whereas 11 of the 17 studies included in our meta-analysis did. Nevertheless, the effect of 
dietary cholesterol on the ratio of total cholesterol to HDL-cholesterol in the studies that failed 
to fulfill our selection criteria was in the same direction as the effect in our meta-analysis. 
This indicates that the present results are not due to a biased selection of the studies. 
Effects in hyperlipemic subjects 
Cholesterol-lowering diets are usually prescribed to hyperlipemic subjects, with 
concentrations of total cholesterol over 5.0 mmol/L (193 mg/dL) (61). However, the mean 
baseline cholesterol concentrations of subjects in the studies that fulfilled our selection criteria 
were below 5.0 mmol/L (193 mg/dL), except for two studies (13,28). The moderately 
hyperlipemic subjects in the study of Chenoweth et al (13) showed an 0.20 units increase in 
the ratio of total cholesterol to HDL-cholesterol upon an increase in dietary cholesterol of 554 
mg per day, whereas the hyperlipemic subjects in the study of Knopp et al (28) showed an 
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0.22 units decrease and the combined hyperlipemic subjects an 0.21 units decrease upon an 
increase in dietary cholesterol of 437 mg per day. The additional analysis with studies that 
failed to fulfill our selection criteria included five studies with mostly moderately 
hyperlipemic subjects (39,50,51,53,54). Due to the limited number of studies, we could not 
analyze these studies separately. Nevertheless, the results of these studies did not clearly differ 
from those in subjects with normal cholesterol concentrations. Therefore, the results of the 
present meta-analysis appear also applicable to hyperlipemic subjects. 
Effects on total cholesterol and on LDL-cholesterol 
The estimated change in total cholesterol of 0.056 mmol/L (2.2 mg/dL) for each 100 
mg per day increase in dietary cholesterol agrees well with changes estimated from other 
meta-analyses (3-5,12). Figure 6.2 suggests that a simple linear model may predict group 
mean changes in LDL-cholesterol concentrations rather well over the normal range of dietary 
cholesterol intakes. Because diet-induced changes in total cholesterol and lipoproteins vary 
considerably between individuals (40,62,63), our results cannot reliably predict changes in 
total cholesterol and lipoproteins in individual subjects or patients. 
Dietary cholesterol and risk of coronary heart disease 
We showed that consumption one additional egg daily, will increase the ratio of total 
cholesterol to HDL-cholesterol by 0.040 units, which would imply an increase in the risk of 
myocardial infarction by 2.1 % (9). The calculated increase in risk may be small in an 
individual patient, but in view of the widespread consumption of diets high in cholesterol it 
may still be substantial at the population level. 
Of course, these calculations do not take into account the effects of other nutrients in 
eggs that may be beneficial in preventing coronary heart disease, such as vitamin E, folate and 
other B vitamins, and unsaturated fatty acids (2). Hu et al (8) calculated that in the USA eggs 
contribute to the intake of many nutrients, such as retinol (4 %), alpha-tocopherol (3 %), folate 
(4 %), other B vitamins (3 % or less), mono-unsaturated fat (3 %), and linoleic acid (2 %). 
However, eggs contributed to 32 % of total dietary cholesterol. Thus, in view of the relatively 
small contribution of eggs to the intake of nutrients that may be beneficial in preventing 
coronary heart disease, the recommendation to limit consumption of eggs may still be valid 
for the prevention of coronary heart disease. Other major sources of dietary cholesterol are 
dairy fats and meat, but these are already considered less favorable for heart disease risk 
because of their saturated fat content. 
In conclusion, the consumption of cholesterol increases the ratio of total cholesterol to 
HDL-cholesterol, which would predict increased risk of coronary heart disease. Therefore, the 
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advice to limit consumption of eggs and other foods rich in dietary cholesterol may still be of 
importance for the prevention of coronary heart disease. 
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Introduction 
The main objective of our research was to determine whether genetic polymorphisms 
affect the response of serum lipids to diet in humans. We found that the effect of genetic 
polymorphisms on lipid response to diet is small. 
The first part of this chapter summarizes the main findings of the studies. The second 
part concerns methodological aspects of studies of the effect of genetic polymorphisms on 
serum lipid response, such as statistical power, multiple testing, effect modification and 
confounding, and extrapolation to other populations. The discussion further focuses on issues 
in comparing these studies, such as the use of different diets and different study populations 
and the possibility of chance findings, using apoprotein (APO)A4 360-1/2 polymorphism as 
an example. And finally, the feasibility of genetic tests to detect diet sensitivity is discussed. 
Recommendations for further research, conclusion, and implications are presented at the end 
of this chapter. 
Main findings 
The pooled analysis of 26 dietary trials showed differences in serum lipid response to 
diet between men and women, and between subjects with various APOE, APOA4, and 
cholesteryl ester transfer protein (CETP) genotypes. Men had larger responses of serum lipids 
to saturated fat and the coffee diterpene cafestol than women. There were no sex differences 
in response to trans fat or dietary cholesterol {Chapter 2). Subjects with the APOE3/4 or 4/4 
genotype tended to have a larger response of low-density lipoprotein (LDL-) cholesterol to 
saturated fat than those with the APOE3/3 genotype. On the contrary, they had similar 
responses to trans fat and dietary cholesterol and they tended to have a smaller response to 
cafestol (Chapter 3). Furthermore, subjects with the APOA4 347-1/1 genotype had smaller 
responses of LDL-cholesterol to diet than those with the APOA4 347-1/2 or 2/2 genotype and 
subjects with the APOA4 360-2/2 genotype had smaller responses than those with the APOA4 
360-1 allele. Subjects with the CETP Taqlb-l allele had smaller responses of HDL-
cholesterol to diet than those with the CETP TaqIb-2/2 genotype. The effects of seven other 
candidate polymorphisms were either inconsistent with results in previous studies or need to 
be replicated in other studies (Chapter 4). Thus, none of the studied polymorphisms had a 
major effect on the response of serum lipids to diet. 
The controlled dietary trial showed that, unlike in some of the previous studies (1,2), 
APOA4 360-1/2 polymorphism did not affect the lipid response to dietary cholesterol in 
healthy women and men (Chapter 5). 
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The meta-analysis that involved 17 studies showed that dietary cholesterol increases 
the ratio of total cholesterol to HDL-cholesterol, which may be a better marker of coronary 
heart disease risk than individual lipid concentrations (3,4)(Chapter 6). 
Methodological issues in studies of genetic polymorphisms and lipid response 
There are several methodological aspects that are important when studying effects of 
genetic polymorphisms on serum lipid response. Below, issues on statistical power, multiple 
testing, confounding and effect modification, and the extrapolation into other populations are 
discussed. 
Number of subjects 
The number of subjects with the rare allele is often a limiting factor in studies of gene-
diet interaction. The smallest group determines the statistical power to detect significant 
effects of a genetic polymorphism on the lipid response to diet (5). 
Especially when the frequency of the rare allele is low, it is hard to find sufficient 
subjects with the rare allele. One way to find sufficient subjects with the rare allele is to pool 
data of various dietary trials. Another way is to screen large numbers of subjects with 
reference to their genotype before the start of a study and select all available subjects with the 
rare genotype. It is also possible to pool subjects heterozygous for the rare allele with those 
homozygous for the rare allele. However, this may not always be appropriate because the 
allele effect may differ between heterozygous and homozygous subjects. 
Multiple testing 
Using the pooled data, we tested differences in response of total cholesterol, HDL-, 
and LDL-cholesterol to saturated fat, trans fat, dietary cholesterol, and cafestol between men 
and women and between genotype groups of 11 polymorphisms. Thus, we performed 144 
statistical tests. The probability of a spurious finding (a) was 0.05. This means that at least 7 
associations may have been chance findings. If we assume that any relation in the data is 
attributable to chance, the probability of at least one statistically significant spurious finding 
will be near 100 %. However, we did not adjust a for multiple testing to reduce the 
probability of chance findings, because the pooled analysis was exploratory rather than 
hypothesis testing, and adjustment for multiple testing would reduce the power to detect 
existing associations (5). 
We knew beforehand that we could not rule out the possibility that some of the 
findings in the pooled analysis might have been due to chance. These findings should 
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therefore be compared to those in previous studies and/or replicated in new dietary trials that 
are especially designed to test the relation between serum lipid response and a candidate gene. 
In addition, the mechanism by which a polymorphism may affect the response, should be 
clarified. 
Effect modification and confounding 
Effect modification and confounding, though different concepts, both involve the 
effect of one extraneous variable on the association between two or more other variables, for 
instance between genetic polymorphism and lipid response. Effect modification will occur if 
the association between genotype and response differs between subjects in various categories 
of the extraneous variable. Confounding will occur if the association is similar between 
subjects in the various categories and the extraneous variable is not evenly distributed 
between subjects with various genotypes (6). Potential effect modifiers and confounders of 
the relationship between genetic polymorphisms and lipid response are body mass index, sex, 
age, and smoking (7-13). Whether an extraneous variable acts as a confounder or as an effect 
modifier can be determined by comparing the association between genotype and response in 
various categories of the extraneous variable. However, this requires a group of subjects that 
is even larger than the one used when studying the main effect of a genetic polymorphism on 
lipid response. Sub-group analyses were not feasible in this study, due to the fact that the 
large numbers of subjects that are needed were not even attained in the pooled analyses. 
Effect modification of the relationship between a genetic polymorphism and response should 
be described. By including confounders as co-variables in a regression model, the 
independent effect of a genotype on response can be estimated. 
Several authors suggest that baseline cholesterol concentration may confound the 
association between genotype and serum lipid response (14,15). One way to adjust for the 
effect of baseline cholesterol concentration is to analyze relative responses, e.g. the 
percentage change from baseline, rather than absolute responses. However, by definition, the 
variance of the relative response is larger than that of the absolute response. This reduces the 
power to detect significant effects of a polymorphism on response. Another way to adjust for 
baseline cholesterol concentration is to use it as a co-variable in a regression model. However, 
if one assumes that differences in response to diet cause differences in concentrations of 
baseline cholesterol, it is, by definition, inappropriate to adjust for baseline cholesterol 
concentration (6). 
120 
General discussion 
Extrapolation into different populations 
Subjects in the pooled analysis (Chapters 2 to 4) and the controlled dietary trial 
(Chapter 5) were mostly young, lean, and had normal cholesterol concentrations. It is not sure 
whether the results also apply to older subjects, obese subjects, or subjects with moderate 
hypercholesterolemia. However, responsiveness to diet does not differ between older and 
younger people (16). If anything, it is less marked in people with a higher body mass index 
(17) and more marked in those with higher cholesterol concentrations (18). Thus, differences 
in lipid response between subjects with various genotypes may be smaller in obese subjects 
than in lean subjects and larger in those with high cholesterol concentrations than in those 
with low cholesterol concentrations. However, several studies found that subject 
characteristics such as age and body mass index, act as effect modifiers on the relationship 
between genotype and serum lipid concentration (10,12). If this is true, the results of the 
studies in this thesis cannot be extrapolated into older subjects with higher body mass index 
and cholesterol concentrations. 
Issues in comparing studies of the effect of a genetic polymorphism on lipid response 
There are several issues to consider when comparing various studies of the effect of a 
genetic polymorphism on lipid response, such as differences in type of dietary treatments 
between studies, differences between men and women, and the possibility of chance findings. 
These issues are also briefly discussed in Chapters 3 to 5. Since the publication of our paper 
on the APOA4 360-1/2 polymorphism from the dietary trial (Chapter 5), several other studies 
have been published. In addition, data regarding our pooled analysis of APOA4 360-1/2 
polymorphism and lipid response (Chapter 4) have become available. Using all data now 
available, we will examine some of the issues in comparing studies on genetic disposition and 
serum lipid response to diet. 
The APOA4 360-1/2 polymorphism and lipid response to diet 
Two independent studies published in 1994 showed that subjects with the APOA4 
360-2 allele had smaller lipid response to diet than those with the APOA4 360-1/1 genotype 
(1,2). However, in several later studies, the difference in lipid response between subjects with 
the various APOA4 360 genotypes was less (19-21), not present (22), or in the opposite 
direction (21,23-25) (Figure 7.1) (95% confidence intervals: personal communications with dr 
R.B. Weinberg and dr J.M. Ordovas, 1999, and Ms L. Heilbronn, 2000). 
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Figure 7.1 Mean difference (with 95% confidence interval) in response of LDL-cholesterol to diet 
between subjects with the apoprotein (APO) A4 360-1/1 and 1/2 genotype in various studies. 
Dietary treatment 
One explanation for these inconsistent findings is that the APOA4 360-1/2 
polymorphism only affects the response of LDL-cholesterol to specific changes in diet. There 
are considerable differences in dietary treatments between studies. The studies of McCombs 
et al (1) and Mata et al (2) showed that the APOA4 360-2 allele attenuates the response of 
LDL-cholesterol to diet. In the study of McCombs et al (1), subjects received additional eggs 
in the high cholesterol period, which might have unintentionally changed fat intake as well. In 
the study of Mata et al (2) the intake of dietary cholesterol and fat was changed, similar to two 
(19,23) of the later studies. Schaefer et al (19) combined some of the data from Mata et al (2) 
with data from other controlled dietary trials and found somewhat less effects than Mata et al 
(2), but in the same direction. On the contrary, Carmena-Ramon et al (23) found that the 
APOA4 360-2 allele, if anything, increases the response of LDL-cholesterol to diet. However, 
the subjects in this study had familial hypercholesterolemia and it is possible that the effects 
of mutations in the LDL-receptor overshadowed the effects of the APOA4 360-1/2 
polymorphism on lipid response. 
Later studies, in which only the intake of cholesterol was changed showed no 
differences between subjects with various APOA4 360 genotypes (21,22). Furthermore, in 
later studies that changed the intake of fat, cafestol, or energy, there were no consistent 
differences between subjects (21,24,25). 
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Thus, effects of the APOA4 360-1/2 polymorphism on the lipid response to dietary 
cholesterol alone, or to fat alone, are small and probably absent. However, it remains possible 
that the APOA4 360-1/2 polymorphism affects the response of serum LDL-cholesterol to a 
change in both saturated fat and dietary cholesterol. 
Sex differences 
Another explanation for discrepancies between studies is that the APOA4 360-1/2 
polymorphism affects the response of LDL-cholesterol in men but not in women. In the study 
of McCombs et al (1), there were 17 men, and only 6 women. In the studies of Mata et al (2) 
and Schaefer et al (19), the effect of the APOA4 360-1/2 polymorphism was limited to men. 
However, in the study of Schaefer et al (19), there were only 5 women with the APOA4 360-
1/2 genotype. The limited number of men and women in most of the other studies does not 
allow for any conclusions to be drawn as to possible sex differences in the effect of APOA4 
360-1/2 polymorphism on lipid response (9,20,21,23,24). Few studies (21,25) comprised 
more than 5 men and 5 women with the APOA4 360-2 allele. Opposite to previous findings 
(1,2,19), men with the APOA4 360-1/2 genotype were slightly more responsive to a low 
energy diet than those with the 1/1 genotype, whereas women with APOA4 360-1/2 genotype 
were slightly less responsive (25). This was also the case with the response of LDL-
cholesterol to trans fat in the pooled analysis (21). There were no differences in the effect of 
the APOA4 360-1/2 polymorphism on the response to cafestol between men and women. 
Similar to the studies of McCombs et al (1) and Mata et al (2), the APOA4 360-2 allele 
attenuated responses of LDL-cholesterol to saturated fat by -0.10 mmol/L in men, whereas the 
2 allele increased it by 0.03 mmol/L in women (21). However, all these findings were the 
result of subgroup analyses that are limited by a small number of subjects with the least-
frequent allele. 
Hence, it is possible that the effect of the APOA4 360-1/2 polymorphism on the 
response to saturated fat and dietary cholesterol is present in men, but not in women. It is also 
possible that the effect of the APOA4 360-1/2 polymorphism may be easier to detect in men 
than in women, because men are more responsive to saturated fat than women (9). 
Chance findings 
The effect of the APOA4 360-1/2 on response of LDL-cholesterol becomes less as 
time goes by (Figure 7.1). This may be an indication that the first studies yielded chance 
findings that could not be replicated in later studies. Such a trend also occurred in other 
studies that were designed to replicate the results of previous studies, as was the case with the 
supposed cholesterol-lowering effect of Lactobacillus Acidophilus (26). This issue stresses 
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the need for multiple studies to assess an effect. An effective way to combine data from prior 
studies with new evidence is the use of Bayesian methods, such as the Bayes Factor (27,28). 
Conclusion 
APOA4 360-1/2 polymorphism probably does not affect the lipid response to diet, at 
least not in every population. It possibly affects the response of LDL-cholesterol to a change 
in saturated fat and dietary cholesterol, and such an effect may be limited to men. However, 
there is no known mechanism that could explain the association between APOA4 360-1/2 
polymorphism and lipid response, and thereby support its possible existence. Therefore, the 
effect of APOA4 360-1/2 polymorphism on lipid response observed in previous studies may 
well have been due to chance. 
Use in clinical practice: prediction of serum lipid response to diet by a genetic test 
One of the rationales for the studies in this thesis was that identification of genetic 
polymorphisms affecting lipid response to diet might help to identify patients with high 
cholesterol concentrations who do not benefit from dietary treatment. A genetic test to predict 
an individual's response to diet would thus allow for a targeted treatment of high cholesterol 
concentrations. 
Before developing such a test, several criteria must be met in establishing medically 
useful links between genetic polymorphisms and serum lipid response (29). The first criterion, 
that the polymorphism causes a relevant functional and/or structural change in the protein, 
does not hold for all polymorphisms studied in this thesis (Table 1.1). The second criterion, 
that the number of subjects with the rare allele is sufficient, is met in most, but not all cases. 
The third criterion, that there should be clear-cut differences in lipid response between 
subjects with various genotypes, is not met either, as there were no major gene effects. The 
last criterion, that there must be a plausible underlying mechanism, does not hold either, 
because the mechanism by which each of the studied polymorphisms may affect the response 
is still unclear. 
All in all, a genetic test on the basis of a single genetic polymorphism to predict an 
individual's response to diet is not feasible in the general population. Patients with familial 
hypercholesterolemia are an exception, due to the fact that testing for the known genetic 
defect in the LDL-receptor meets all the above criteria. 
The question remains whether it will eventually be possible to accurately predict an 
individual's response to diet on the basis of genetic testing. The response to diet depends on a 
combination of genetic and environmental factors. The correlation of lipid response to diet 
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with genetic polymorphisms is weak and different combinations of genetic and environmental 
factors may lead to a similar response. Nevertheless, we cannot rule out the possibility that in 
the future there will be a test that predicts an individual's response to diet on the basis of a 
combination of genetic and environmental factors. This test may be useful in clinical practice, 
because screening subgroups that are prone to high cholesterol concentrations will help to 
select the most suitable preventive measures or therapy. However, there is no basis for 
population-wide screening. It is highly unlikely that the costs will counterbalance the benefits. 
Besides, one should be aware that genetic testing is a sensitive issue that will encounter many 
ethical barriers. Therefore it should be used with caution (30). 
Recommendations for future research 
We suggest several directions for future research. 
In general, studies of genetic polymorphisms and lipid response to diet may provide 
new data with regard to the role of proteins involved in cholesterol metabolism and may thus 
contribute to additional insight in the cholesterol metabolism. 
Our studies have been performed in healthy and lean subjects. Dietary studies using 
different populations, such as diabetic subjects, would also be of interest, because these 
conditions may modify the association between genetic polymorphisms and lipid response to 
diet. 
The APOA4 360-1/2 polymorphism may affect the response of LDL-cholesterol to a 
change in saturated fat and dietary cholesterol, and such an effect may be limited to men. A 
new controlled dietary trial with sufficient numbers of men and women per genotype group, 
should be performed to test these hypotheses. 
Several candidate genes were not studied in this thesis, such as the genes encoding 
scavenger receptor Bl, 7-ot-hydroxylase, ATP-binding cassette 1, and peroxisome proliferator 
activated receptor-a. Polymorphisms of these genes should be studied further in relation to 
lipid metabolism and lipid response to diet (31,32,33,34). 
Cholesterol metabolism involves a large number of proteins, and thus, genes. There 
are several methods available in animal studies to identify which genes play a role in the 
response to a specific dietary component. Serial analysis of gene expression and micro-array 
analyses are methods for obtaining a complete inventory of expressed genes in a particular 
organ or cell type. Human genes, that are homologous to the genes identified with these tools 
in animals, are candidate-genes for studies on gene-diet interaction. The first step is to 
identify single-nucleotide polymorphisms of a candidate gene. The next step is to define 
haplotypes of the candidate gene, which are series of alleles found at linked loci on a single 
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genotype, possibly by using parental DNA of each participant. The last step consists of testing 
genetic polymorphisms and lipid response to diet in randomized trials under carefully 
controlled dietary conditions. 
The mechanism by which dietary components increase serum lipids is still not 
understood. Evaluation of specific molecular processes underlying dietary responsiveness 
remains a major challenge. 
The long-term goals of the studies described above should be to determine the diet-
gene interaction affecting atherosclerosis in humans. 
Main conclusion and implication 
The effect of genetic polymorphisms on serum lipid response to diet is small. It is 
therefore not possible to identify individuals who will not benefit from a cholesterol-lowering 
diet on the basis of a specific genetic polymorphism. 
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World wide, cardiovascular diseases are a substantial source of chronic disability and 
health costs. Subjects at high risk of cardiovascular disease or who suffer from overt 
cardiovascular disease should be targeted for lifestyle intervention and, where appropriate, 
drug therapies. One of the changes in lifestyle is a lipid-lowering diet, which is low in dietary 
cholesterol and saturated fat. However, even though a lipid-lowering diet is effective for most 
people, it is not for all. Identification of genetic factors that are related to the dietary-induced 
change in cholesterol concentrations, the lipid response, may be of help in the identification of 
subjects who will not benefit from a cholesterol-lowering diet. It may also clarify the role of 
certain proteins in cholesterol metabolism. 
The objective of our research was to determine whether genetic polymorphisms affect 
the response of serum lipids to diet in humans. 
We first assessed sex differences in the response of serum lipids to changes in the diet 
(Chapter 2). For this purpose, we pooled data on the serum lipid response to diet from 26 
former dietary trials. We used lipid responses to dietary saturated fat in seven trials involving 
126 men and 147 women, to dietary trans fat in two trials (48 men and 57 women), and to 
dietary cholesterol in eight trials (74 men and 70 women). We also measured responses to the 
coffee diterpene cafestol, which occurs in unfiltered coffee, in nine trials (72 men and 61 
women). All subjects were lean and healthy. The response of total cholesterol to saturated fat 
was 0.14 mmol/L (mean) larger in men than in women (95% confidence interval (CI), 0.04 to 
0.23 mmol/L). The response of total cholesterol to cafestol was 0.22 mmol/L larger in men 
than in women (95% CI, 0.04 to 0.39 mmol/L). Responses to trans fat and to dietary 
cholesterol did not differ significantly between men and women. In conclusion, men have 
larger responses of total cholesterol to saturated fat and cafestol than women. 
We also used these data to study the effect of apoprotein (APO) E (Chapter 3) and 10 
other genetic polymorphisms (Chapter 4) on responses of serum lipids to various dietary 
treatments. For this purpose, we combined data on lipid responses to saturated fat, to trans fat, 
to dietary cholesterol, and to cafestol with newly obtained data on 11 genetic polymorphisms 
in 405 mostly normolipidemic subjects. The responses of low-density lipoprotein (LDL-) 
cholesterol to saturated fat were 0.08 mmol/L larger in subjects with the APOE3/4 or E4/4 
genotype than in those with the APOE3/3 genotype (95% CI, -0.01 to 0.18 mmol/L). In 
contrast, responses of LDL-cholesterol to cafestol were 0.11 mmol/L smaller in subjects with 
APOE3/4 or E4/4 genotype than in those with APOE3/3 genotype (95% CI, -0.29 to 0.07 
mmol/L). Responses to dietary cholesterol and trans fat did not differ significantly between 
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subjects with various APOE genotypes. The response of serum LDL-cholesterol to diet was 
somewhat smaller in subjects with the APOA4 347-1/1 genotype than in those with APOA4 
347-2 allele and it was smaller in subjects with APOA4 360-2/2 genotype than in those with 
APOA4 360-1 allele. Subjects with cholesteryl ester transfer protein (CETP) Taqlb-l allele 
had smaller responses of high-density lipoprotein (HDL-) cholesterol to diet than those with 
CETP TaqIb-2/2 genotype. The effects of the other seven candidate polymorphisms were 
either inconsistent with results in previous studies or need to be replicated in other studies. In 
conclusion, polymorphisms in APOE, APOA4, and CETP genes may affect the lipid response 
to diet. 
We further studied the effect of the APOA4 360-1/2 polymorphism on response of 
serum lipids to dietary cholesterol in a controlled dietary trial specially designed for this 
purpose (Chapter 5). To this end, 10 men and 23 women with the APOA4 360-1/1 genotype 
and 4 men and 13 women with the APOA4 360-1/2 or 2/2 genotype (carriers of the APOA4 
360-2 allele) were fed two diets high in saturated fat, one containing cholesterol at 136 
mg/day, and one containing cholesterol at 948 mg/day. Each diet was supplied for 29 days in 
a crossover design. The mean response of serum LDL-cholesterol was 0.44 mmol/L in both 
subjects with the APOA4 360-1/1 genotype and in those with the APOA4 360-2 allele (95 % 
CI of difference in response, -0.20 to 0.19 mmol/L). The mean response of HDL-cholesterol 
was also similar, 0.10 mmol/L, in the two APOA4 360 genotype groups (95 % CI of 
difference in response -0.07 to 0.08 mmol/L). In conclusion, the APOA4 360-1/2 
polymorphism did not affect the response of serum lipids to a change in cholesterol intake in 
this group of healthy Dutch subjects who consumed a background diet high in saturated fat. 
Although it is not directly related to the relation between genetic factors and serum 
lipid response, we also used the data of this trial to review the effect of dietary cholesterol on 
the ratio of total cholesterol to HDL-cholesterol, which is a more specific predictor of 
coronary heart disease than either lipid value alone (Chapter 6). The other studies were 
identified by MEDLINE and Biological Abstracts searches (1974 - June 1999) and by 
reviewing reference lists. Studies were included if they had a crossover or parallel design with 
a control group, if the experimental diets only differed in the amount of dietary cholesterol or 
eggs and were each fed for at least 14 days, and if concentrations of HDL-cholesterol were 
reported. Of the 222 studies identified, 17 studies met all of these criteria. Extraction of data 
on design of the study, subject characteristics, composition and duration of the diets, and 
concentrations of serum lipids was done by the same investigator. Addition of 100 mg dietary 
cholesterol to daily intake increased the ratio of total cholesterol to HDL-cholesterol by 0.020 
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units (95% CI, 0.010 to 0.030), the concentration of total cholesterol by 0.056 mmol/L (95% 
CI, 0.046 to 0.065 mmol/L), and the concentration of HDL-cholesterol by 0.008 mmol/L 
(95% CI, 0.005 to 0.010 mmol/L). In conclusion, dietary cholesterol raises the ratio of total 
cholesterol to HDL-cholesterol, which would predict increased risk of coronary heart disease. 
Therefore, the advice to limit consumption of eggs and other foods rich in cholesterol may 
still be of importance for the prevention of coronary heart disease. 
In conclusion, the effect of genetic polymorphisms on serum lipid response to diet is 
small. It is therefore not possible to identify individuals who will not benefit from a 
cholesterol-lowering diet on the basis of a specific genetic polymorphism. 
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Samenvatting 
Wereldwijd zijn hart- en vaatziekten de meest voorkomende chronische ziekte. 
Mensen die een hoog risico op hart- en vaatziekten hebben of die aan hart- en vaatziekten 
lijden, krijgen het advies hun leefstijl te veranderen. Verder ontvangen zij, indien nodig, 
medicatie. Een van de veranderingen in leefstijl is een cholesterolverlagend dieet, dat weinig 
voedingscholesterol en verzadigd vet bevat. Een cholesterolverlagend dieet is effectief voor 
de meeste mensen maar niet voor iedereen. Wanneer erfelijke factoren die gerelateerd zijn aan 
de effectiviteit van een dieet bekend zijn, zal dit het identificeren van mensen die niet gebaat 
zijn bij een cholesterolverlagend dieet vergemakkelijken. Het kan verder bijdragen aan kennis 
over de rol van verschillende eiwitten in het cholesterolmetabolisme. 
Het doel van ons onderzoek was om te bepalen of genetische polymorfismen 
veranderingen in het serum cholesterolgehalte, de cholesterolrespons, die het gevolg zijn van 
veranderingen in de voeding beinvloeden. 
Als eerste onderzochten we of mannen en vrouwen verschillend reageren op 
veranderingen in de voeding (Hoofdstuk 2). Hiervoor combineerden we gegevens over de 
cholesterolrespons op voeding uit 26 vroegere dieetstudies. We beschikten over gegevens 
over de cholesterolrespons op verzadigd vet uit zeven studies met 126 mannen en 147 
vrouwen, op trans vet uit twee studies (48 mannen en 57 vrouwen) en op voedingscholesterol 
uit acht studies (74 mannen en 70 vrouwen). Verder beschikten we over gegevens over de 
respons op het koffiediterpeen cafestol, dat voorkomt in ongefilterde koffie, uit negen studies 
(72 mannen en 61 vrouwen). 
De respons van totaalcholesterol op verzadigd vet was 0,14 mmol/L (gemiddelde) 
groter in mannen dan in vrouwen (95% betrouwbaarheidsinterval (bti), 0,04 tot 0,23 mmol/L). 
De respons van totaalcholesterol op cafestol was 0,22 mmol/L groter in mannen dan in 
vrouwen (95% bti, 0,04 tot 0,39 mmol/L). De responsen op trans vet en voedingscholesterol 
verschilden niet tussen mannen en vrouwen. Hieruit concluderen we dat mannen een grotere 
respons van totaalcholesterol op verzadigd vet en cafestol hebben dan vrouwen. 
We gebruikten deze gegevens ook om het effect te bestuderen van het apoprote'ine 
(APO) E (Hoofdstuk 3) en tien andere genetische polymorfismen (Hoofdstuk 4) op de 
cholesterolrespons op verschillende dieetbehandelingen. Hiervoor combineerden we de 
gegevens over de cholesterolrespons op verzadigd vet, trans vet, voedingscholesterol en de 
koffiediterpeen cafestol met nieuw verkregen gegevens over 11 genetische polymorfismen in 
405 personen van wie het merendeel normale cholesterolwaardes had. 
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De respons van lage-dichtheid liproteine (LDL-) cholesterol op verzadigd vet was 0,08 
mmol/L groter in personen met het APOE3/4 of 4/4 genotype dan in degenen met het 
APOE3/3 genotype (95% bti, -0,01 tot 0,18 mmol/L). Daarentegen was de respons van LDL-
cholesterol op cafestol 0,11 mmol/L kleiner in personen met het APOE3/4 of 4/4 genotype 
dan in degenen met het APOE3/3 genotype (95% bti, -0,29 tot 0,07 mmol/L). De responsen 
op voedingscholesterol en trans vet verschilden niet tussen personen met de verschillende 
APOE genotypen. De respons van LDL-cholesterol was enigszins kleiner in personen met het 
APOA4 347-1/1 genotype dan in degenen met het APOA4 347-2 allel en het was kleiner in 
personen met het APOA4 360-2/2 genotype dan in degenen met het APOA4 360-1 allel. 
Personen met het cholesterylestertransfer-eiwit (CETP) Taqlb-l allel hadden kleinere 
responsen van hoge-dichtheid lipoprotei'ne (HDL-) cholesterol op voeding dan degenen met 
het CETP TaqIb-2/2 genotype. De effecten van de andere zeven kandidaat polymorfismen 
kwamen niet overeen met die uit vorige studies of moeten eerst nog worden bevestigd in 
nieuwe studies. Hieruit concluderen we dat het APOE, het APOA4 347, het APOA4 360 en 
het CETP Taqlb polymorfisme de cholesterolrespons op voeding mogelijk bei'nvloeden. 
We bestudeerden het effect van het APOA4 360-1/2 polymorfisme op de 
cholesterolrespons op voedingscholesterol verder in een gecontroleerde dieetstudie die 
hiervoor speciaal was opgezet (Hoofdstuk 5). Hiervoor aten 10 mannen en 23 vrouwen met 
het APOA4 360-1/1 en 4 mannen en 13 vrouwen met het 1/2 of 2/2 genotype (dragers van 
het 2 allel) twee dieten hoog in verzadig vet, een met 136 mg/dag aan cholesterol en een met 
948 mg/dag aan cholesterol. Elk dieet werd verstrekt gedurende 29 dagen in cross-over vorm. 
De gemiddelde respons van LDL-cholesterol was 0,44 mmol/L in zowel personen met het 
APOA4 360-1/1 genotype als personen met het APOA4 360-2 allel (95% bti van het verschil 
in respons, -0,20 tot 0,19 mmol/L). De gemiddelde respons van HDL-cholesterol was 
eveneens gelijk, 0,10 mmol/L, in de twee APOA4 360 genotypengroepen (95% bti van het 
verschil in respons, -0,07 tot 0,08 mmol/L). Hieruit concluderen we dat het APOA4 
polymorfisme de cholesterolrespons niet bei'nvloedt in gezonde Nederlanders die een 
achtergrondvoeding aten met veel verzadigd vet. 
Hoewel het niet direct gerelateerd is aan de relatie tussen erfelijke factoren en de 
cholesterolrespons, gebruikten we de gegevens van deze studie verder voor een meta-analyse 
naar het effect van voedingscholesterol op de ratio totaal- ten opzichte van HDL-cholesterol 
{Hoofdstuk 6). Deze ratio is een specifiekere maat voor het risico op hart- en vaatziekte dan de 
afzonderlijke lipideniveaus. We verzamelden de andere studies met behulp van MEDLINE en 
Biological Abstracts (1974 - juni 1999) en met het bekijken van referentielijsten. De 
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insluitingcriteria waren dat de studies een cross-over of parallelle opzet met een controlegroep 
hadden, dat de dieten in de studies alleen verschilden in de hoeveelheid voedingscholesterol 
of eieren en dat ze minstens 14 dagen verstrekt werden, en dat de HDL-cholesterol 
concentraties werden vermeld. Van de 222 gei'dentificeerde studies voldeden er 17 aan deze 
criteria. Het verzamelen van de gegevens over studieopzet, persoonskenmerken, 
samenstelling en duur van de voedingen en de serum cholesterol concentratie is uitgevoerd 
door een onderzoeker. 
Een dagelijkse consumptie van 100 mg cholesterol per dag extra verhoogde de ratio 
van totaal- ten opzichte van HDL-cholesterol met 0,020 eenheden (95% bti, 0,010 tot 0,030), 
de totaalcholesterol concentratie met 0,056 mmol/L (95% bti, 0,046 tot 0,065 mmol/L) en de 
HDL-cholesterol concentratie met 0,008 mmol/L (95% bti, 0,005 tot 0,010 mmol/L). We 
concluderen dat voedingscholesterol de ratio van totaal- ten opzichte van HDL-cholesterol 
verhoogt, wat samenhangt met een verhoogd risico op coronaire hartziekte. Dus, het advies 
om matig te zijn met het eten van eieren is zeker van belang voor de preventie van coronaire 
hartziekte. 
De conclusie van dit proefschrift is, dat de invloed van genetische polymorfismen op 
de cholesterolrespons klein is. Het is dan ook niet mogelijk om op basis van informatie over 
een specifiek genetisch polymorfisme mensen te identificeren die niet gebaat zijn bij een 
cholesterolverlagend dieet. 
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